Assessment of the immunogenicity of porcine Circovirus 2 (PCV2) vaccines : a prototype vaccine and a lambda display vaccine by Angunna Gamage, Lakshman Nihal
ASSESSMENT OF THE IMMUNOGENICITY OF PORCINE 
CIRCOVIRUS 2 (PCV2) VACCINES: A PROTOTYPE VACCINE AND A 
LAMBDA DISPLAY VACCINE 
 
 
 
A Thesis Submitted to the College of Graduate Studies and 
Research in Partial Fulfillment of the Requirements for the Degree 
of Doctor of Philosophy in the Department of Veterinary 
Microbiology University of Saskatchewan  
Saskatoon  
By 
Lakshman N. A. Gamage 
 
© Copyright Lakshman N. A. Gamage, March 2010. All rights reserved
i 
 
PERMISSION TO USE 
In presenting this thesis in partial fulfillment of the requirements for a doctorate of 
philosophy degree in Veterinary Microbiology from the University of Saskatchewan, I agree that 
permission for copying of this thesis in any manner, in whole or in part, for scholarly purposes 
may be granted by the Head of the Department of Veterinary Microbiology. It is understood that 
any copying, publication or use of this thesis or parts thereof for financial gain shall not be 
allowed without written permission. It is also understood that due recognition shall be given to 
me and to the University of Saskatchewan in any scholarly use which may be made of any 
material in my thesis. 
 Requests for permission to copy or to make other use of material in this thesis in whole or 
in part should be addressed to: 
Head of the Department of Veterinary Microbiology 
University of Saskatchewan 
Saskatoon, Saskatchewan 
S7N 5B4 
 
 
 
 
 
 
 
 
 
 
 
ii 
 
ABSTRACT 
Porcine Circovirus 2 (PCV2) associated diseases (PCVAD) cause economic loss to the 
global swine industry. Control measures for PCVAD largely depend on the use of PCV2 
vaccines. The available commercial PCV2 vaccines contain either inactivated whole virus 
particles or recombinant PCV2 capsid protein. These preparations most likely contain varying 
amounts of immune-irrelevant proteins that can cause adverse injection site reactions, with 
compromised efficacy due to alteration of protective immune epitopes arising during the viral 
inactivation process. Other constraints include high production cost attributed to propagation of 
slow growing virus and expression and extraction of recombinant proteins, a requirement for 
adjuvants, and the induction of a Th2-biased immune response. Hence, development of new 
PCV2 vaccines is necessary.  
There are two recommended PCV2 vaccination strategies. They are i. vaccinating sows, 
which relies on the passive transfer of maternal immunity to offspring, and ii. immunizing young 
piglets to induce an active immune response. The piglet vaccination has been shown to confer 
better protection from mortality. Maternal antibody interference to the induction of an active 
immune response is an obstacle when piglets are vaccinated at an early age. Can we sidestep this 
maternal antibody interference?  To address this issue, I investigated whether a prototypical 
PCV2 vaccine, parenterally administered, could override maternally-derived PCV2 antibodies in 
seropositive piglets. The results of this study were not conclusive. However, they laid the 
foundation for future studies based upon using varying levels of vaccine antigen with different 
adjuvants, and administered to piglets with defined maternally derived PCV2 antibodies.   
Subsequently, I examined if a new PCV2 vaccine candidate comprised of bacteriophage 
lambda particles displaying part of the PCV2 capsid protein could induce anti-PCV2 immunity. 
Initial experiments showed that pigs do not have pre-existing anti-lambda antibodies and thus 
will not neutralize display particles used as a vaccine at primary vaccination. I produced and 
characterized lambda phage particles displaying four immunodominant regions of porcine 
circovirus 2 (PCV2) capsid protein fused to the lambda capsid protein D i.e., D-CAP, phage 
display particles. Expression of D-CAP in Escherichia coli (E. coli) and its presence in the 
vaccine preparation was shown by ELISA and Western blots using anti-PCV2 polyclonal 
antiserum from a gnotobiotic pig. The vaccine, lambda particles displaying PCV2 capsid protein 
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immunogenic epitopes fused to lambda D protein (LDP-D-CAP), administered without an 
adjuvant induced both humoral and cellular immunity to PCV2 in conventional pigs, as shown 
by ELISA, Western blots, virus neutralization assay and delayed type hypersensitivity (DTH) 
reactions. This work produced the first potential phage vaccine to PCV2. In order to further 
investigate the feasibility of using the lambda display technology. I produced and characterized 
two additional lambda display particle preparations, LDP-D-FLAG and LDP-D-GFP, displaying 
a FLAG tag and the green fluorescent proteins, respectively.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
ACKNOWLEDGEMENTS 
I express my sincere thanks and deep sense of gratitude to my supervisors, Drs. John Ellis and 
Sidney Hayes, for their assistance, support and guidance throughout my journey to achieve what 
I am passionate about in my life.     
I greatly appreciate the contributions and expertise of my supervisory committee, Drs. Steve 
Krakowka, Debbie Haines, John Harding and the Graduate Chair, Dr. Vikram Misra.      
I thank Ms. Connie Hayes and Carrie Rhodes for their excellent technical assistance, Dr. Hans-
W. Ackermann at the Department of Medical Biology, Faculty of Medicine, Laval University, 
Quebec, for electron microscopy imaging, Dr. Sarah Parker at the Dept. of Large Animal 
Clinical Sciences, Western College of Veterinary Medicine (WCVM), for helping me with data 
analysis and staff members in Animal Care Unit and Glassware & Media Preparation Laboratory 
at WCVM for their help.  
I acknowledge the support rendered by Ms. Patricia Thompson, Asma Amin and Lana Abey 
throughout my stay at the Department of Veterinary Microbiology.  
I extend my appreciation to Dr. Norman Rawlings (Associate Dean, Research) and the rest of the 
Interprovincial Graduate Student Fellowship Committee at WCVM for granting me a fellowship 
and NSERC & Continues Research Funds for research expenses. 
 I am grateful to my wife, Podimanike Dissanayake and daughter, Sanuthi Nihansi Gamage for 
their unconditional love, ever-willing help, patience and constant encouragement in achieving 
my academic goals.    
 
 
 
 
 
v 
 
TABLE OF CONTENTS 
 
PERMISSION TO USE  ............................................................................................................. i 
ABSTRACT  ............................................................................................................................... ii 
ACKNOWLEDGEMENTS ......................................................................................................iv 
TABLE OF CONTENTS  ..........................................................................................................v 
LIST OF TABLES  ....................................................................................................................xi 
LIST OF FIGUERS  .................................................................................................................xii 
LIST OF ABBREVIATIONS  ................................................................................................xvii 
CHAPTER 1. INTRODUCTION  ............................................................................................1 
1.1. CIRCOVIRIDAE  .................................................................................................................1 
1.2. Torque teno virus (TTV)  ......................................................................................................1 
1.3. PORCINE CIRCOVIRUSES (PCVs)  ..................................................................................2 
1.3.1. PCV genome organization ..................................................................................................2 
1.3.2. PCV proteins/replication ....................................................................................................2 
1.3.3. Genetic differences between PCV1 and PCV2  .................................................................3 
1.3.4. Pathogenicity differences between PCV1 and PCV2  ........................................................4 
1.3.5. Genetic differences among PCV2 isolates and their emergence ........................................4 
1.3.6. PCV life cycle  ....................................................................................................................6 
1.3.7. Biological and Physico-chemical properties of PCV  ........................................................8 
1.3.8. Propagation, isolation and purification of PCV  ................................................................8 
vi 
 
1.3.9. Detection & quantification of PCV antigens/proteins  .....................................................9 
1.3.10. PCV Epidemiology & measuring antibodies  ................................................................9  
1.3.11. Post-weaning multisystemic wasting syndrome (PMWS)  ..........................................10 
1.3.12. PCV2 pathogenesis  ......................................................................................................12 
1.3.13. Likely mechanism of wasting in PMWS affected pigs  ...............................................15 
1.3.14. Economic impact of PCV2 infections  .........................................................................16 
1.3.15. PCV2 control strategies  ...............................................................................................16 
1.3.15.1. Improved management practices  ..............................................................................16 
1.3.15.2. PCV2 vaccines  ..........................................................................................................17   
1.4. BACTERIOPHAGE IN GENERAL  ................................................................................18 
1.5. BACTERIOPHAGE TECHNOLOGY APPLICATIONS IN VETERINARY  ...............22 
 MEDICINES  
1.5.1. PHAGE THERAPY  .......................................................................................................22 
1.5.2. BACTERIOPHAGE DISPLAY SYSTEMS  .................................................................24 
1.5.3. BACTERIOPHAGE VACCINES  .................................................................................25 
1.5.3.1. Phage display vaccines  ...............................................................................................25 
1.5.3.2. Phage DNA vaccines  ..................................................................................................26 
1.5.4. BACTERIOPHAGE DIAGNOSTIC REAGENTS  ......................................................26 
HYPOTHESIS ........................................................................................................................28 
OBJECTIVES  .......................................................................................................................28 
CHAPTER 2: EFFICACY OF PARENTERAL VACCINATION AGAINST ...............29 
  PORCINE CIRCOVIRUS 2 (PCV2) IN SEROPOSITIVE PIGLETS 
1. Introduction  .........................................................................................................................29 
vii 
 
2. Materials and methods  ........................................................................................................30 
2.1. Formulation of the vaccine  ..............................................................................................30 
2.2. Preparation of challenge inocula  .....................................................................................30   
2.2.1. Spleen tissue homogenate  .............................................................................................30 
2.2.2. Tissue culture lysate  .....................................................................................................30  
2.3. Experimental design  .......................................................................................................31 
2.4. Serology  ..........................................................................................................................32 
2.4.1. Antigen capture ELISA  ...............................................................................................32  
2.4.2. Competitive ELISA (cELISA)  ....................................................................................32 
2.5. Histology and Immunohistochemistry (IHC)  .................................................................33  
2.6. Statistical analyses  ..........................................................................................................34 
3. Results  ...............................................................................................................................34 
3.1. PCV2-specific antibody responses  .................................................................................34 
3.2. Clinical signs and gross lesions  ......................................................................................35 
3.3. Histology and IHC  ..........................................................................................................35 
4. Discussion  ..........................................................................................................................41 
CHAPTER 3: IMMUNOGENICITY OF LAMBDA PHAGE PARTICLES ................44 
  DISPLAYING PORCINE CIRCOVIRUSS 2 (PCV2) CAPSID    
  PROTEIN IMMUNODOMINANT REGIONS   
1. Introduction  .......................................................................................................................44 
2. Materials and methods  ......................................................................................................45  
2.1. Designing a gene fusion expressing immunogenic regions of PCV2 cap protein ..........45 
viii 
 
2.2. Determining if pigs contain pre-existing anti-lambda antibodies ..................................46 
2.2.1. Raising anti-lambda antisera in pigs ...........................................................................46 
2.2.2. Gnotobiotic and farm pig sera (field sera)  .................................................................46 
2.2.3. Indirect ELISA (iELISA) measuring anti-lambda antibodies  ...................................46 
2.3. Demonstrating expression of D-CAP in transformed E. coli cells ................................47 
2.3.1. Protein extraction ........................................................................................................47 
2.3.2. Dot blot assay .............................................................................................................47 
2.3.3. iELISA ........................................................................................................................48 
2.4. Preparation of LDP-D-CAP vaccine  ............................................................................49 
2.5. iELISA for phage displaying recombinant D-CAP protein............................................49 
2.6. Evaluation of porcine Circovirus 2 phage display vaccine ...........................................49 
2.6.1. Immunization trial 1  ..................................................................................................49 
2.6.2. Immunization trial 2  ..................................................................................................50 
2.6.3. Skin testing for delayed type hypersensitivity (DTH) reaction ..................................50  
2.6.4. iELISA measuring anti-lambda and anti-PCV2 antibodies  .......................................51 
2.6.5. Virus neutralization assay (VNA)  .............................................................................51 
2.6.6. Immunoblots ...............................................................................................................52 
2. Results  ...........................................................................................................................52 
3.1. Raising anti-lambda hyperimmune sera in pigs  ...........................................................52 
3.2. Determining if pigs contain pre-existing anti-lambda antibodies  ................................53 
3.3. Assessing for the expression of D-CAP fusion protein in 594 [pD-CAP] ...................53 
 cell extracts       
ix 
 
3.4. Demonstrating D-CAP displayed in LDP vaccine ......................................................53 
3.5. Anti-lambda and anti-PCV2 antibody response following phage display  .................53
 vaccination  
3.6. Monitoring body weight, general health and injection site reactions .........................54 
3.6. Immunoblots  ..............................................................................................................54 
3.7. DTH reaction ..............................................................................................................54 
4. Discussion  .....................................................................................................................69 
CHAPTER 4: PREPARATION OF LAMBDA DISPLAYING FUSION  ................75 
  POLYPEPTIDES   
1. Introduction  ..................................................................................................................75 
2.1. Demonstration of thermoregulated expression from lambda promoter  ....................75  
2.1.1. Thermal induction of cell killing  ...........................................................................75 
2.1.2. Thermal induction of susceptibility to lambda infection ........................................76 
2.2. Protein extraction  ......................................................................................................76 
2.3. Demonstration of D-fusion proteins in E. coli cell extracts by .................................76
 Western blots (WB)  
2.4. Preparation and purification of lambda particles displaying D-fusion proteins ........77 
2.5. Viable phage counts by plaque assay  .......................................................................78 
2.6. Total phage counts  ...................................................................................................78 
2.7. Demonstration of phage displaying D-CAP by indirect ELISA (iELISA)  ..............79 
2.8. Demonstration of phage displaying D-CAP by WB  ................................................79 
2.9. Electron microscopy ..................................................................................................80 
3. Results  .........................................................................................................................80 
3.1. Demonstration of thermoregulated expression from lambda promoter ....................80 
 
 
x 
 
3.2. Demonstration of D-CAP and D–FLAG fusion proteins in E. coli cell ...................80  
  extracts by WB   
3.3. Monitoring bacterial growth and viable phage counts during preparation ...............81  
  of lysates of lambda displaying D-fusion proteins 
3.4. Viable (pfu/ml) phage titers in lysates and purified lambda display ........................81  
  preparations  
3.5. Banding pattern of lysates containing lambda displaying D-CAP  ..........................81  
  expressed in two different expression systems  
3.6. Characterization of phage bands of lambda displaying D-fusion proteins  ..............82 
3.6.1. Banding pattern, densities, viable and total phage titers of lambda  .....................82  
  displaying D-fusion proteins after first CsCl purification  
3.6.2. Demonstration of phage displaying D-CAP by ELISA  .......................................82  
3.6. 3. Demonstration of phage displaying D-CAP by WB  ...........................................83 
3.6.4. Electron microscopy of lambda displaying D-CAP ..............................................83 
4. Discussion  ..................................................................................................................93 
GENERAL CONCLUSIONS  .....................................................................................98 
REFERENCES  ............................................................................................................99 
 
 
 
 
 
 
xi 
 
LIST OF TABLES 
CHAPTER 2 
Table 2.1. Number of pigs with histological lesion in H & E stained sections of ...............39 
 left inguinal and gastric lymph nodes. 
Table 2.2. Immunohistochemistry scores for the presence of PCV2 antigens in ...............40         
 two lymph nodes.  
CHAPTER 3 
Table 3.1. PCV2 neutralizing antibody titers of pigs immunized with...............................68 
 LDP-D-CAP compared to one pig receiving lambda control.   
Table 3.2. Delayed type hypersensitivity (DTH) reaction scores in H & E .......................68 
 stained skin biopsy tissues from pigs vaccinated with lambda phage and   
 partially purified PCV2 antigens from PK-15 infected cell lysate and their   
 respective placebo; PBS and uninfected PK-15 lysate following phage   
 display vaccine trial. 
CHAPTER 4 
Table 4.1. Monitoring of phage titers (pfu/ml) in lysates of lambda displayed  ...............92  
 D-CAP stored at 4
o
C. 
Table 4.2. Titers (pfu/ml) of phage displaying fusion proteins after each ........................92 
 step of the preparation.  
 
 
 
 
 
xii 
 
LIST OF FIGURES 
CHAPTER 2 
Fig. 2.1. cELISA measuring anti-PCV2 immune responses in individual ...........................36 
 control pigs receiving  PCV2- uninfected PK 15 cell lysate mixed    
 1:1 with an adjuvant,  twice at 3-week intervals, followed by oral   
 challenge with PCV2 inoculums. 
Fig. 2.2.  cELISA measuring anti-PCV2 immune responses in individual ..........................37 
 vaccinates receiving inactivated PCV2- infected PK 15 cell lysate    
 mixed 1:1 with an adjuvant,  twice at 3-week intervals, followed by   
 oral challenge with PCV2 inoculums. 
Fig. 2.3. Box and whisker plot for net change in cELISA values in controls ......................38 
 and vaccinates  following primary vaccination (Week 1 to Week 4),   
 booster (Week 1 to Week 7) and the challenge (Week 1 to Week 10).   
 There was a significantly (P < 0.05) smaller decline in cELISA PCV2  
 antibody levels in vaccinates compared to controls following booster  
 vaccination (Week 1 to Week 7). 
CHAPTER 3 
Fig. 3.1. The anti-lambda immune response measured by ELISA in three .........................56 
 pigs each receiving 3×10
8
, 3×10
9
 or 3×10
10 
phage particles per    
 Kg b.wt. (3X) at 2-week intervals in comparison to the background   
 OD (open bars). Values are the mean + standard error (SE). 
Fig. 3.2. The anti-lambda antibody response measured by ELISA in  ...............................57 
 individual  pigs receiving 3×10
8
 (hatched bar), 3×10
9
 (open bar)    
 or 3×10
10 
(closed bar) phage particles per Kg b.wt. (3X) at 2-week intervals. 
 
 
xiii 
 
Fig. 3.3. Pre-existing anti-lambda antibody levels in sera from eight  ...................................58 
 gnotobiotic pigs (negative control) and sera from 55 conventional    
 pigs from five different farms (field sera) were measured by ELISA and  
 compared to an anti-lambda hyperimmune serum (positive control).   
 Values are the mean + standard error (SE) for gnotobiotic and field sera. 
Fig. 3.4. Dot-blot assay detecting D-CAP fusion protein in E. coli cell extract ....................59 
 using anti-PCV2 polyclonal antiserum from a gnotobiotic pig; a) E. coli   
 R594 cell extract, b) E. coli 594 [ pD-CAP], c) PCV2 antigen-positive   
 control and d) lambda phage  antigen-negative control. The total protein   
 applied per blot site was: a) 165 µg b) 165 c) 5 µg of partially purified   
 PCV2 antigen from PK-15 infected cells and d) 1×10
8 
unmodified phage  
 particles. 
Fig. 3.5. Results of ELISA measuring D-CAP fusion protein in an E. coli cell extracts .......60 
 using anti-PCV2 polyclonal antiserum from a gnotobiotic pig. Serial dilutions  
 were made of a protein extract obtained from R594 [pD-CAP] E. coli cells (■).  
 Corresponding dilutions were made of a protein extract obtained from R594  
 E. coli  cells (▲). The total protein coated per well at 1:5th dilution was 21.5 µg. 
Fig. 3.6. Results of ELISA measuring phage displayed D-CAP fusion protein using...........61
 anti-PCV2  polyclonal antiserum from a gnotobiotic pig. Serial dilutions of  
 LDP-D-CAP vaccine (■) were made. Corresponding dilutions were made of an 
 equivalent number of unmodified lambda phage particles (▲). The number of  
 phage particles in the undiluted preparation was 3×10
10 
per well. 
Fig. 3.7. Results of ELISA measuring anti-lambda antibody responses in two ...................62 
 vaccinated pigs (closed & open bars) receiving 1 × 10
10
 LDP-D-CAP per   
 Kg b.wt. intradermally without incorporating an adjuvant, 3X at 2-week  
 intervals, and a control pig (hatched bars) receiving similar doses of unmodified  
 lambda particles. 
 
xiv 
 
 
Fig. 3.8. Results of ELISA measuring anti-PCV2 antibody responses in two ....................63 
 vaccinated pigs (closed & open bars) receiving 1 × 10
10
 LDP-D-CAP   
 per Kg b.wt. intradermally without incorporating an adjuvant, 3X at 2-week 
 intervals, and a control pig (hatched bars) receiving similar doses of unmodified   
 lambda particles. 
Fig. 3.9. Results of ELISA measuring anti-lambda immune antibody responses ..............64 
   in six vaccinated pigs receiving 1 × 10
10
 LDP-D-CAP per Kg b.wt.  
 intradermally without incorporating an adjuvant, 3X at 2-week intervals   
 (closed bars), and six controls (open bars) receiving similar doses of  
 unmodified lambda particles. Values are the mean + standard error (SE). 
Fig. 3.10. Results of ELISA measuring anti-PCV2 antibody response in six .....................65  
 vaccinated pigs receiving 1 × 10
10
 LDP-D-CAP per Kg b.wt. intradermally 
 without incorporating an adjuvant, 3X at 2-week intervals (closed bars), and six  
 controls (open bars) receiving similar doses of unmodified lambda particles. 
 Values are the mean + standard error (SE).    
Fig. 3.11. Western blots demonstrating phage displayed D-CAP fusion protein  ..............66  
 using: (a) anti-PCV2 polyclonal antiserum from a gnotobiotic pig; (b serum  
 from a pig prior to vaccination; and (c) serum from a pig after vaccination.  
 Lanes;  1) Protein mass marker, 2) partially purified PCV2 antigen from PK-15  
  infected cells, 3) LDP-D-CAP from heat-disrupted phage particles, and   
 4) similarly disrupted unmodified phage particles. Arrow indicates D-CAP protein.  
 Triangle points to PCV2 cap protein (positive control). 
Fig. 3.12. Photographs of representative DTH reaction scores: (a) 0, (b) 1+, (c) 2+ ........67 
 and (d) 3+ based scoring of H & E stained skin biopsy tissues. Original  
 magnification (a-d): Magnification ×50. The scale is 0=negative, 1+=minimal,  
 2+=moderate, and 3+=Extensive 
 
xv 
 
CHAPTER 4 
Fig.4.1. Thermal induction inactivates heat-labile lambda repressor as manifested ...........84 
 by cell killing or susceptibility to a homologous lambda infection: (a) lysogen  
 used to transform plasmids coding for D-FLAG were killed at 42
o
C, (b) immune  
 to homologous lambda infection (λc172) at 30oC but (c) become susceptible for  
 the infection at 42
o
C. Arrows indicate direction of cross streaking. 
Fig. 4.2. Western blots demonstrating expression of D-CAP and D-FLAG in E. coli ........85
 transformed with respective plasmids by thermal induction for varying   
 periods of incubation: (a) D-CAP at 42
o
C and (b) D-FLAG 39
o
C.     
 “No induction” corresponds to extracts from cells containing the plasmid   
 but not thermally induced. “No plasmids” indicate that the cells were not   
 transformed with plasmids but were thermally induced. Other lanes are labelled  
 by duration of incubation. 
Fig. 4.3. Growth curve of E. coli transformed with pD-CAP during the preparation of ......86 
 lysate containing lambda displayed D-CAP at 39
o
C.  Growth medium was  
 inoculated with E. coli at point a. Optical densities (OD575) and viable phage  
 titers (pfu/ml) were measured from point a through g. Time of phage infection  
 (arrow) and titers thereafter were indicated along with the corresponding stage  
 of incubation. 
Fig.4.4. The banding pattern of lambda displayed D-CAP in CsCl gradients produced .....87 
 using two expression systems: (a) λimm434cI infection in E. coli lacking   
 thermoregulatory promoter activity transformed with pD-CAP (D-CAP  
 expressed constitutively) (b) λimm434cI infection in E. coli containing   
 thermo regulatory promoter transformed with pD-CAP (D-CAP expressed by 
 thermal induction). Phage bands were identified by eitheir location in the tube.  
 The top cream layer was protein excluded from the gradient. 
 
 
xvi 
 
Fig.4.5. The banding pattern of lambda displaying (a) D-CAP (b) D-FLAG and  ............88  
(c) D-GFP in CsCl gradients produced by lambda infection in thermally               
induced E. coli containing respective plasmids at 39
o
C. The densities of        
each band are indicated by arrows. 
Fig.4.6. ELISA measuring phage displayed D-CAP fusion protein using anti-PCV2 ......89
 polyclonal antiserum from a gnotobiotic pig. Serial dilutions of middle (   )  
 and bottom bands (■) of lambda D-CAP preparation along with unmodified  
 lambda (▲) contain equivalent number of phage particles. The number of   
 phage particles in the  undiluted preparation was 3×10
10 
per well. 
Fig.4.7. Western blots demonstrating lambda displayed D-CAP and other major ...........90 
lambda   proteins: (a) blot reacted with anti-PCV2 polyclonal antiserum        
from a gnotobiotic  pig, (b) anti-D-CAP polyclonal antiserum from a              
conventional pig and (c) anti-lambda polyclonal antiserum from a conventional           
pig. Lanes; 1) Protein mass marker, 2) partially purified PCV2 antigen from         
PK-15 infected cells, 3) LDP-D-CAP from heat-disrupted phage particles, and                
4) similarly disrupted unmodified phage particles. Arrow, triangle and arrow               
with double heads indicates D-CAP, PCV2 cap (positive control) and lambda                  
D proteins respectively. Major lambda protein bands are identified on the blot (c). 
Fig. 4.8. Electron microscopy of lambda displayed D-CAP: (a) crude lysate and  ...........91                          
(b) twice CsCl purified middle band of lambda D-CAP preparation               
demonstrating tailless heads in comparison to (c) intact particles in an              
unmodified lambda lysate. Arrows and triangles indicate hexagonal relatively    
bigger heads and rounded smaller proheads respectively. Magnification ×148,500. 
 
 
 
 
xvii 
 
LIST OF ABBREVIATIONS 
aa   Amino acid 
b.wt.   Body weight 
CMI Cell-mediated immunity 
D-CAP  Immunodominant regions of porcine circovirus 2 capsid                   
protein fused to the lambda head protein D  
D-FLAG  FLAG tag protein fused to lambda head protein D 
D-GFP  Green fluorescent protein fused to lambda head protein D 
DTH    Delayed type hypersensitivity reactions 
ELISA   Enzyme-linked immunosorbent assay 
cELISA   Competitive ELISA  
iELISA  Indirect ELISA  
LDP  Lambda display particles 
LDP-D-CAP  Lambda particles displaying D-CAP 
LDP-D-FLAG  Lambda particles displaying D-FLAG 
LDP-D-GFP  Lambda particles displaying D-GFP 
H & E    Haematoxylin and Eosin stain 
hpi.   Hour/s post infection 
IHC    Immunohistochemistry   
IPMA   Immunoperoxidase monolayer assay 
IFA   Immunofluorescence assay  
xviii 
 
MW   Molecular weight 
MDA   Maternally-derived antibodies 
nt.   Nucleotide  
OD    Optical density 
ORF   Open reading frame 
Ori   Origin of replication 
PCV   Porcine circoviruses   
PCV1    Porcine Circovirus 1  
PCV2    Porcine Circovirus 2  
PCVAD  Porcine Circovirus 2 associated diseases 
PMWS   Post-weaning multisystemic wasting syndrome  
pfu   Plaque forming unit 
PBS   Phosphate buffer saline 
PDB   Phage dialysis buffer 
PK-15   Pig kidney 15 cell line 
TTV   Torque teno virus  
UTR   Untranslated region 
TCID50  50% Tissue Culture Infective Dose 
VNA    Virus neutralization assay  
VLP   Virus-like particles 
WB   Western blot
1 
 
CHAPTER 1. INTRODUCTION 
1.1. CIRCOVIRIDAE 
 The family Circoviridae is classified into three genera of plant and animal viruses, 
Circovirus, Gyrovirus and Anellovirus [1]. Circoviruses are non-enveloped icosahedral virus 
particles with single-stranded circular DNA genome [2]. Members of the Circovirus genus 
include three plant viruses i.e., Banana bunchy top virus (BBTV), Coconut foliar decay virus 
(CFDV) and Subterranean clover stunt virus (SCSV), two porcine viruses namely porcine 
Circovirus type 1 (PCV1) and type 2 (PCV2) and several avian viruses such as Psittacine beak 
and feather disease virus (BFDV), Columbid or Pigeon circovirus (CoCV or PiCV), Canary 
circovirus, Goose circovirus (GCV) and duck circovirus (DuCV) [1, 3-6]. Chicken anaemia virus 
(CAV) is the only member of the Gyrovirus genus. Torque teno virus (TTV) and Torque teno 
mini virus (TTMV) are classified into the Anellovirus genus [1].  
1.2. Torque teno virus (TTV) 
 Torque teno virus (TTV) is circular single stranded non-enveloped DNA virus (ssDNA), 
similar in structure to porcine Circoviruses, identified in humans, pigs, poultry, cattle, sheep, 
dogs and cats [1, 7]. Three open reading frames (ORFs) were described for TTV genome 
characterized for pigs i.e., ORF1=635 amino acids (aa) capsid protein, ORF2=73 aa replication 
protein, ORF3=224 aa (of unknown function) [7, 8]. The size of a cloned pig TTV genome, 
named Sd-TTV31 (GenBank accession # AB076001.1), is 2878 nucleotides (nt.) which included 
an untranslated region (UTR) of ~24% nt. containing regulatory sequences required for 
transcription and replication [7, 8]. Phylogenetic analysis of TTV genome from pigs and other 
domestic animal species revealed species specificity. Two genotypes of pig TTVs were 
identified with nucleotide (nt.) sequence homology varying between 44-70%. However, greater 
homology was observed among pig isolates from the same geographic region [7]. No evidence of 
a TTV link to human disease has been found [7]. Inoculation of gnotobiotic pigs first with TTV 
and subsequently by PCV2 was shown to induce post-weaning multisystemic wasting syndrome 
(PMWS) [9] indicating a likely role of TTV in pathogenesis of PMWS. A higher prevalence of 
TTV infection was reported in PMWS affected pigs than healthy pigs [10]. 
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1.3. PORCINE CIRCOVIRUSES (PCVs) 
1.3.1. PCV genome organization 
 PCVs are 16-18 nm in diameter containing a genome of approximately 1760 nt. They are 
the smallest mammalian viruses yet known and encode two major open reading frames, rep and 
cap [3, 5, 11]. The respective gene products, Rep and Cap perform most elementary viral 
functions namely, replication and packaging of the viral genome. The rep and cap genes are 
oriented head-to-head and the resulting ambisense genome organization creates two intergenic 
regions (IR), a shorter region between 3′-ends of rep and cap and a larger one between their 5′ 
ends [3, 11]. The latter IR is comprised of origin of replication (Ori) characterized by stem loop 
structure with a nonamer 5′ T/AAGTATTAC sequence at its apex flanked by an inverted repeat 
(palindrome) of 11 nt. and three adjacent hexamer 5’-CGGCAG motifs [3]. The 3′-part of the 
stem and the two proximal hexmers serve as the binding sites for replicases. The stem loop 
structure is indicated as a common feature of viruses that replicate via rolling-circle replication 
(RCR) [3, 11]. The nonamer sequence 5′ T/AAxTAxTAC at the apex of the loop is termed the 
essential core element (ECE) as it plays a key role in PCV replication and stable infectious virus 
production while “x” positions can be substituted without functional loss [12].  
1.3.2. PCV proteins/replication 
 The largest ORF, ORF1 or rep is on the viral plus-strand transcribed clockwise into two 
collinear replicase proteins i.e., Rep, full length transcript (PCV1: 312 aa; PCV2: 314 aa) and 
Rep′, a truncated and C-terminal frame-shifted transcript (PCV1: 168 aa; PCV2: 178 aa). Both 
Rep and Rep′ are necessary to initiate PCV replication [3, 5, 11]. Rep recognizes the right arm of 
the palindrome while Rep′ binds to the two proximal tandem repeat hexamers (H1 and H2) at the 
Ori [5]. Moreover, Rep and Rep′ of PCV1 and PCV2 can recognize their respective binding sites 
interchangeably between these two viruses and initiate DNA replication [13]. Promoter of rep 
(Prep) is negatively regulated by Rep on binding to two inner hexamers (H1 and H2). However, 
Rep′ does not exert such repression of Prep attributed to differential capability of Rep and Rep′ to 
interact with transcription factors [5].  
 ORF2 or cap is on the minus-strand transcribed counter clockwise into the major 
structural capsid protein, Cap (PCV1: 232 aa; PCV2: 233 aa) promoter (Pcap) which is mapped 
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within the rep gene [3, 11]. Rep, Rep′ or Cap do not influence the transcription initiated at Pcap. 
Cap is the main antigenic determinant of PCV [14, 15] and, has a molecular weight (MW) ~28 
kDa [3, 16]. It contains an arginine-rich basic N-terminus which is highly conserved among 
PCV2 isolates and is believed to have DNA binding activity in the native virion [3, 17, 18]. 
Synthesis of PCV2-Cap in an insect cell line (Sf9) using a baculovirus expression system 
demonstrated formation of empty capsid heads referred to as “virus like particles” [19]. There 
are two additional ORFs (ORF3 and ORF4) described on the PCV genome both of which 
mapped within ORF1 and are transcribed counter clock wise (opposite of ORF1 transcription 
direction) [11, 17]. Expression of ORF3 was shown in PCV2 infected PK-15 cells and found to 
play a role in virus induced cell death by apoptosis [20]. Transfection experiments with an ORF3 
deficient PCV2 mutant showed that the protein is not essential for viral replication.   
 Rep, Rep′ and Cap carry nuclear localization signals (NLS). In PCV infected cells, Rep 
and Rep′ co-localized in the nucleoplasm. In contrast, Cap is localized in the nucleoli in the early 
stage of the infection and later migrates to the nucleoplasm and is then exported into the 
cytoplasm. The intracytoplasmic inclusions were found dispersed throughout the cytoplasm but 
were most numerous in the perinuclear cytoplasm [21]. Since all PCV-encoded proteins localize 
in the nucleus, encapsidation of the viral genome is considered to occur in the nucleus [11].   
1.3.3. Genetic differences between PCV1 and PCV2 
 Analysis of genetic variations between PCV1 and PCV2 revealed a greater nt. homology, 
~80%, between rep genes compared to cap with ~62% homology [3, 16]. Overall nt. homology 
was 68% between PCV1 and PCV2 isolates [22] forming two distinct clusters by phylogenetic 
analysis [23]. These analyses showed that PCV1 and PCV2 are genetically different.  Overall nt. 
sequence comparison among PCV2 isolates revealed > 94% homology [17, 24]. The nt. 
homology was much greater among PCV2 isolates within a geographic region; homology among 
European and North American isolates were 99.8% and 99.5% respectively [17]. Amino acid  
sequence comparison among PCV2 isolates between Rep and Cap proteins was 99-100% and 90-
100% respectively [25, 26]. Amino acid sequences analysis of the Cap protein of PCV2  isolates 
from healthy and diseased pigs recognized  three regions of heterogeneity i.e., 59-80, 121-136 
and 180-191 [25] and the first two regions correspond with two of the immunodominant regions 
identified by Pepsacan analysis [14].  It was speculated that these regions might be exposed to 
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selective immune pressure and, therefore, are candidate regions for involvement in emergence of 
new PCV2 variants. However, these studies were unable to identify a molecular marker for 
PCV2 pathogenicity, as similar aa sequence patterns were found in isolates from both healthy 
and sick pigs. Further, origin of replication and rep genes of PCV1 and PCV2 are highly 
conserved, replication proteins are functionally exchangeable and replication efficiency is 
comparable in vitro. Therefore, the replication strategy of the two viruses is not the key element 
determining their distinct pathogenicity [13]. These data indicate that the PCV2 genome, notably 
rep gene, is relatively stable. 
 A unique restriction enzyme site Nco1 is present only in the PCV2 genome. A universal 
PCR-restriction fragment length polymorphism assay (PCR-RFLP) was developed based on this 
feature to distinguish PCV1 and PCV2 genomes. The assay yields two fragments for PCV2   
compared to single undigested PCV1 genome following digestion with Nco1 enzyme. Detection 
of three fragments is indicative of the presence of both PCV1 and PCV2 DNA in the sample 
[18].  
1.3.4. Pathogenicity differences between PCV1 and PCV2 
 PCV1 was first discovered as a contaminant in the pig kidney PK-15 cell line (ATCC-
CCL31) [27], and was later shown to be non-pathogenic in rabbits, mice and pigs [28-30] and is 
not linked to any disease condition. In contrast, PCV2 was isolated  initially [31] and 
subsequently world-wide, from diseased pigs suffering from what was later described as post-
weaning multisystemic wasting syndrome (PMWS) [26, 32-36]. Experimental inoculation of 
pigs with PCV2 confirmed its pathogenicity [28, 37-46]. The difference in pathogenicity 
between PCV1 and PCV2 was not linked to any specific genetic differences between the two 
viruses [47].  
1.3.5. Genetic differences among PCV2 isolates and their emergence  
  PCV2 DNA was detected in both PMWS-affected (100%) and healthy pigs (76%) [24].  
Further, multiple PCV2 strains were detected in a single pig, most often in PMWS affected pigs 
[48, 49]. Studies demonstrated evidence of emerging new PCV2 variants as a result of 
recombination events with simultaneous multiplication of multiple PCV2 strains in a single host 
animal [48-50] or a cell line [51]. Propagation of viral inoculums prepared from PMWS-affected 
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pigs in PK-15 cells showed the emergence of a perfect mosaic PCV2 strain as a result of 
recombination events that occurred between two parental strains in the rep and cap genes [51].  
Nucleotide sequences of three PCV2 strains isolated from PMWS-affected pigs from different 
farms were compared to 164 PCV2 nucleotide sequences obtained from GenBank to determine 
their phylogenetic origin [50]. Evidence for potential recombination events was analysed using 
recombination detection software (RDS) package [50]. These analyses revealed that the three test 
strains fell into two of the seven parental PCV2 lineages, named A through G, providing 
evidence for natural recombination events occurred among different PCV2 strains. The potential 
recombination sites were identified within the origin of replication and the rep gene. Similar 
phylogenetic analysis with nt. sequences of 148 PCV2 isolates demonstrated a high degree of 
homology, yet formed into two major groups, groups 1 and 2 consist of eight sub-clusters i.e., 
1A-1C and 2A-2E [23]. The RDS programming revealed that the PCV2 strains within cluster 1B 
evolved by recombination events between isolates from clusters 1A and 2D. The two PCV2 
groups differ from each other in their total number of nt. sequences; PCV2-group 2 have 1768 nt. 
compared to PCV2-group 1 with a single nt. deleted  at 1040 position in the C-terminal of cap 
gene resulting in a change in aa sequence at 232 position, i.e., K232N [24, 52]. Further, each 
group has stretches of distinct nt. and aa sequences, and signature motifs [52]. Analysis of 
nucleotide sequence for the cap gene of PCV2 strains from PMWS affected and non affected 
herds revealed consistent detection of PCV2-group 1 in the former group, while the latter 
reported exclusively genogroup 2 [48]. PCV2-group 1 was detected in the United States for the 
first time during a severe outbreak of PMWS during 2005-2006 [52]. Simultaneously, a dramatic 
increase in PCV2-group 1 associated deaths was reported in Canada [53]. These observations led 
to speculation that the more pathogenic PCV2 strains belong to PCV2-group 1. In contrast, other 
studies could neither identify a direct link between a particular PCV2 genogroup and the 
development of PMWS [48, 54], nor any PCV2 molecular marker linked to virulence and, 
therefore, associated with severe PMWS outbreaks [24, 25]. However, a PCV2 strain with point 
mutations on the capsid protein, raised following serial passage in PK-15 cell culture, had 
significant attenuation of virulence following inoculation into 3-4 weeks old specific-pathogen 
free (SPF) pigs. This finding is indicative of the presence of likely virulent determinants on the 
PCV2 capsid protein (PCV2-Cap) [55]. Germ-free pigs inoculated with varying doses of either 
PCV2 group 1 or -2 had similar pathology and mortality rates (~ 50% mortality) [56]. 
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Gnotobiotic pigs administered  PCV2-group 1 and -2 alone, or in combination with keyhole 
limpet hemocyamin in incomplete Freund’s adjuvant (KLH/ICFA), did not develop clinical 
disease and lesions were  indistinguishable among the groups [57]. However, overt PMWS was 
produced when gnotobiotic pigs were inoculated with either group of virus initially by 
intraperitonial route, followed by intransal administration of a heterogonous strain 1 week later, 
irrespective of the order of administering the inoculums [58]. Gross and histological lesions were 
significantly greater in the heterologous challenge groups compared to groups that received 
single or double homologous inoculums. These findings suggest that the recent upsurge of 
PMWS cases in North America could be due to dual heterologous infection [58]. Nomenclature 
was established to designate different PCV2 groups. PCV2-group 1 that were to have caused 
severe PMWS outbreaks in recent years was classified as PCV2b and PCV2-group 2 that was 
discovered in 1997 and continued to be encountered  in both clinical and healthy pigs was 
classified as PCV2a  [48, 59]. A vaccine containing PCV2-Cap of a genotype 2 had shown cross 
protection against heterologous strains originated from two geographic regions i.e., Europe and 
North America [60], indicating genetic differences among PCV2 isolates do not likely affect 
critical protective epitopes.  
1.3.6. PCV life cycle 
 PCV2 antigens are predominantly detected in monocyte/macrophage lineage cells and 
follicular dendritic cells in infected pigs [61-63]. In vitro, both PCV1 and PCV2 are most 
commonly propagated in porcine kidney (PK-15) cells [27, 64-66]. Therefore, the mechanism of 
PCV2 attachment and internalization kinetics have been studied by in vitro infection experiments 
using a porcine monocytic cell line, 3D4/31 and PK-15 cells, and using PCV2 or PCV2 virus like 
particles (VLP) [67-69].  Glycosaminoglycans, such as heparin sulfate (HS) and chondroitin 
sulfate B (CS-B) were shown to serve as the cell surface receptors on 3D4/31 and PK-15 cells 
[67]. This study constituted several experiments to demonstrate specific binding of PCV2 to 
immobilized heparin (heparin-Sepharose column), reduction of binding on the cell surface and 
percentage of infected cells by prior incubation of target cells with heparin, HS and CS-B due to 
competition or enzymatic treatment of cells to remove cell surface HS and CS-B. The findings 
were confirmed by demonstrating marked reduction of PCV2 infection in a mutant cell line 
deficient in HS and CS-B compared to wild type PCV2 competent Chinese hamster ovary (CHO) 
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cells. The finding that HS and CS-B serving as cell surface receptors is more relevant since  
PCV2-Cap is reported to contain a  putative heparin binding motif [67]. However, finding that 
HS and CS-B deficient cells were unable to abrogate PCV2 infection completely led to 
investigation of other mechanisms of viral entry into cells, such as clathrin- or caveolae-mediated 
endocytosis and macropinocytosis. In one such study in 3D4/31 cells, there was co-localization 
of PCV2 VLP and clathrin by double immunofluorescence staining [69]. Further, this study 
demonstrated a significant decline in PCV2 infection by chemical inhibition of clathrin-mediated 
endocytosis, cellular actin polymerization and endosomal acidification using lysomotrophic 
weak bases such as ammonium chloride and chloroquine diphosphate (CQ), but not by inhibition 
of caveolae-mediated endocytosis or macropinocytosis. Cellular actin polymerization plays a 
positive role in clathrin-mediated endocytosis [70] and gradual pH drop in the endosomal 
maturation process, i.e., early endosomal pH of 6.0-6.8 drops to ~5.0 in lysosomes, is reported to 
enhance uncoating and escape of the virus into cytoplasm [69]. The effect of the inhibition of 
endosome-lysosome system on PCV2 infection was further investigated using several epithelial 
cell lines [68]. In contrast to the findings with the porcine monocytic cell line 3D4/31, PK-15 
cells showed an increased PCV2 infection following the inhibition of endosome-lysosome pH 
during the early stage of infection (up to 6 hr) [68]. This effect was not observed when cells were 
treated with CQ 1 hr prior to or 12 hr after the infection. Further investigation revealed that 
serine proteases increase PCV2 infection in both 3D4/31and PK-15, irrespective of pH 
alterations in the endosome-lysomes compartment, by aiding the disassembly of viral capsid. In 
summary, heparin sulfate and chondroitin sulfate B serve as the cell surface receptors for PCV2 
attachment. Virus is internalized by clathrin-mediated endocytosis dependent on the cellular 
actin polymerization process. Serine protease dissembles PCV2-Cap and aids in uncoating the 
virus. Single stranded (ss) DNA is transported into the nucleus and converted by host DNA 
polymerases into the double stranded (ds) intermediate. The rep and cap mRNAs are transcribed, 
proteins are synthesized and imported into the nucleus. Rep and Rep′ bind to dsDNA to initiate 
DNA replication by rolling circle replication (RCR) [4]. Assembly and release of PCV virions 
are not yet studied [11].   
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1.3.7. Biological and Physico-chemical properties of PCV 
The PCV2 particle, has a diameter of ~20.5 nm and an icosahedral structure with 60 
capsid protein molecules arranged in 12 pentamer units [71]. PCV1does not haemagglutinate 
erythrocytes from a wide range of species, has buoyant density of ~1.37 g/ml in a CsCl gradient, 
is resistant to treatment with chloroform, is stable at pH 3.0, and during incubation at 56
o
C or 
70
o
C for 15 min [6, 72]. PCV can be disrupted by heating at 100
o
C for 1 min with Sodium 
dodecyl sulphate (SDS) and mercaptoethanol to demonstrate proteins by polyacrylamide gel 
electrophoresis [27].    
1.3.8. Propagation, isolation and purification of PCV 
 Several cell lines originating from different animal species were shown to be permissive 
to PCV infection [21, 67-69, 72, 73]. However, only pig-derived and Vero cell cultures showed 
an increase in viral titers following the second passage of the virus. Vero cells were derived from 
fibroblasts from an African Green monkey. The other cell lines examined showed a reduction or 
elimination of viral infection following the second passage of the virus [72]. The porcine kidney 
(PK-15) cell line is the most commonly used cell culture in propagation of PCV [27, 64-66]. A 
study on the kinetics of PCV2 replication in PK-15 cells revealed an increase in viral antigens, 
RNA transcripts and progeny viruses in a time dependent manner. Considerable differences in 
replication kinetics were observed among PCV2 strains tested. Using polyclonal antiserum, viral 
antigens of Stoon-1010 isolate of PCV2 were detected in the cytoplasm starting from 12 hr post-
infection (hpi), and reaching a maximum percentage of virus positive cells (1.8%) by 48 hpi. A 
rise in the viral titer in the culture supernatant was observed at 36 hpi and coincided with 
appearance of the first foci of infected cells, indicating a duration of 24-36 h for the full 
replication cycle of PCV2 in PK-15 cells [74].  Both Rep and Cap proteins were detected in the 
nucleus at 12 hpi by using double immunofluorescence staining. PCV2 does not result in 
cytopathic effects [75]. However, the numbers of detaching cells that contain Cap abundantly 
present in their cytoplasm increased starting from 48 hpi [74]. The number of PCV2 infected 
cells was increased by 50 fold following treatment of the cell culture with d-glucosamine-HCl at 
4-6 hpi. PCV DNA replication depends on cellular enzymes expressed during the S phase of 
growth, and DNA replication starts only once the cells have passed mitosis. It was shown that 
PCV DNA, by itself, is incapable of penetrating the nuclear membrane and, therefore, must be 
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included in the daughter nuclei following mitosis. Glucosamine is reported to aid the entry of 
PCV DNA in to the cell nucleus [76]. However, PCV2 virus titers do not generally exceed 10
5
 
TCID50 per ml when the virus is propagated in PK-15 cells [61, 65, 66]. Hence, a number of 
studies have used PCV2 virus-like particles in place of intact virus for experiments that required 
large amounts of viral protein [67-69]. The low viral titers in PK-15 cells were reported to be 
because of its heterogeneous cell population, i.e., constituted of cells with varying 
permissiveness to PCV2 [65]. Therefore, a new cell line (PK-C1) comprised of a homogenous 
high permissive cell population was generated following a selection procedure for  permissive 
cells from parental PK-15 cell culture. The new cell line was reported to produce higher viral 
yield (10
8
 TCID50 per ml) [65]. PCV1 and PCV2 DNA were also shown to be infectious and 
produce progeny virus in PK-15 cell cultures [17, 27, 76, 77]. Cell culture grown virus can be 
isolated following three freeze/thaw cycles of infected cells and initial low speed centrifugation 
followed by ultracentrifugation of the supernatant. The pellet is suspended in phosphate buffer 
saline (PBS, pH 7.2) and a follow up sucrose or CsCl gradient centrifugation used to purify the 
virus [27, 65, 72, 78].         
1.3.9. Detection & quantification of PCV antigens/proteins 
 PCV antigens on acetone-fixed tissue impressions, cryostat sections, formalin-fixed 
paraffin-embedded tissues or viral infected tissue cultures can be detected by 
immunohistochemistry using PCV1 or 2 specific mAbs [31, 39, 79, 80]. PCV DNA in tissue 
sections can similarly be detected by in situ hybridization using virus specific probes [31, 80-82]. 
Indirect immunofluorescence [79], immunoperoxidase monolayer assay (IPMA) [83] and antigen 
capture ELISA [79, 84] methods are employed to detect and quantify viral antigens. Polymerase 
chain reaction (PCR) methods are widely used to detect PCV DNA in formalin-fixed tissues 
[85], semen [86]  blood/serum/plasma [87-90], faeces and other excreta [91, 92]. PCV proteins 
are demonstrated by heating purified virus in a reducing buffer at 100
o
C for 1 min [27] or 95
o
C 
for 5 min [93] to disrupt the particles, followed by SDS-PAGE and Western blots [27, 93].   
1.3.10. PCV Epidemiology & measuring antibodies  
 Serological surveys indicate that antibodies to PCV2 are prevalent in swine herds, with or 
without PMWS, globally [72, 83, 87, 94-101]. There are reports indicating that the prevalence of 
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PCV2 antibodies within a herd could be higher in PMWS-affected herds compared to non-
affected herds [83, 102], or be equally high in both groups [95, 98]. The high prevalence of 
PCV2 antibodies compared to PMWS incidence indicates that PCV2 is well adapted to its host 
and subclinical infection prevails. IPMA [83, 95] and indirect immunofluorescence assay (IFA) 
[103] demonstrated a greater prevalence of antibodies to PCV2 antibodies compared to PCV1. 
This observation is in accord with that of a lower occurrence of PCV1 tissue DNA (6.4%) 
compared to PCV2 (14.7%) detected by PCR in healthy pigs [26].  Further, a larger proportion  
of PCV1 seropositive pigs had PCV2 antigens in their tissues compared to pigs without 
containing PCV2 antigens [83], suggesting that PCV2 infection possibly can induce cross 
reactive antibodies to PCV1.  Pigs containing  PCV1 antibodies but negative for PCV2 
antibodies were reported, although in low prevalence [103]. Competitive enzyme-linked 
immunosorbent assay (cELISA) using monoclonal antibodies (mAb) were developed to measure 
anti-PCV2 antibodies [79, 94]. In addition, indirect ELISA (iELISA) methods were developed to 
measure anti-PCV2 antibodies using either recombinant PCV2-Cap protein  [99, 102, 104-106] 
or PCV2 infected cell lysate [107] as coating antigens. Sera from humans and a range of animal 
species including cattle, sheep, pigs, goats, chickens, turkeys, rabbits and mice tested by IFA did 
not contain anti-PCV antibodies [72]. In a similar experiment, antibodies reactive to purified 
PCV1 antigens were detected using IFA and ELISA in human, cattle and mice but these results 
were suggested to result from cross reactive antibodies caused by related species specific viruses 
[93].  
1.3.11. Post-weaning multisystemic wasting syndrome (PMWS) 
 PMWS, one of the PCV2 associated diseases (PCVAD), was first recognized by a group 
of scientists at the University of Saskatchewan in several high health herds in Western Canada in 
1998 [31, 108, 109] and subsequently reported worldwide [17, 26, 31-36, 50, 52, 100, 110-112]. 
PMWS causes considerable economic losses to the swine industry [113]. In recent years, there 
was an upsurge in severe outbreaks in Europe and North America [52, 53, 59]. The most 
prominent clinical signs are wasting, dyspnoea, enlarged lymph nodes, diarrhoea, pallor, and 
jaundice. The clinical manifestations are usually restricted to the post-weaned aged groups, 
between 7 and 15 weeks, particularly affecting pigs in late nursery and early grower stages [114, 
115]. Serosurveys indicate virtually all commercial herds are infected, although only a small 
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proportion of pigs develop the disease [98, 99, 103, 115]. Experimentally reproduced [28, 37, 39, 
40, 42, 43] or naturally occurring PMWS cases [116-119] have increased severity of lesions and 
higher mortality rates when pigs are concurrently infected with other common pathogens of pigs 
such as porcine parvo virus (PPV), porcine reproductive and respiratory syndrome virus 
(PRRSV), swine influenza virus and Mycoplasma hypopneumoniae. Mortality rates up to 30% 
were reported on farms experiencing such multiple infections [120].  Death of affected animals 
(case fatality rate) can be as high as 70-80% [121].  
 Since PCV2 was first isolated from the Canadian index farm, several studies have 
attempted to reproduce the clinical disease by inoculating PCV2 alone or in combination with 
other co-pathogens in order to fulfil Koch's postulates in different experimental pig models 
including conventional pigs, with or without colostrum deprivation, inoculated with PCV2 and 
PRRSV [42, 43], conventional pigs inoculated with PCV2 alone [40, 45, 46] or in combination 
with PPV [40], SPF pigs inoculated with PCV2 tissue homogenate [41] or cloned PCV2 DNA 
[122, 123], gnotobiotic pigs inoculated with PCV2 in combination with PPV [28, 39], immune 
stimulation with KLH/ICFA [38] or immune suppression [124]. These experiments had varying 
levels of success in reproducing the disease. Discrepancies were mainly attributed to the 
differences in the pig model and the challenge inocula/method used. However, the gnotobiotic 
pig model with immune stimulation produced clinical disease in all inoculated pigs and fulfilled 
Koch's postulates [38]. Production of disease with inocula containing cloned PCV2 DNA 
supported the latter finding and confirms PCV2 is the primary/essential cause of PMWS. 
Therefore, the role of co-pathogens is considered to be  that of a potentiating factor [125]. PCV2 
has also been incriminated in other diseases including porcine dermatopathy nephropathy 
syndrome (PDNS) [126-128],  porcine respiratory disease complex (PRDC) [129],  reproductive 
disorders [130] and proliferative and necrotizing pneumonia [131]. 
 Diagnosis of PMWS is based on combination of number of criteria i.e., i. typical clinical 
signs, ii. characteristic microscopic lesions, and iii. demonstration of viral antigens and/or 
nucleic acid associated with histological lesions in affected pigs [75, 116]. None of these criteria 
separately or demonstration of antibodies is indicative of the PMWS, since healthy pigs can 
harbour PCV2 in their tissues and have serum antibodies.  
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1.3.12. PCV2 pathogenesis   
PCV2 persists as a subclinical infection in most commercial pig herds [83, 95, 98, 99] and the 
virus maintains a stable relationship with the host in spite of seroconversion [132]. Both healthy 
and diseased pigs shed virus/viral DNA in excretions and secretions [92] contaminating the 
premises. The virus is stable and persists in the environment for prolonged periods of time, 
resulting in the exposure of newborn piglets [72, 75, 121]. The mode of infection is widely 
believed to be through the oronasal route [121]. Maternal antibodies have partial protective 
capacity [133]. However, these decay after weaning, reaching minimum levels by 9-10 weeks 
which coincides with viremia (viral DNA by PCR), viral excretion and elevation of PCV2 
antibodies [87, 92, 134]. Although not proven, epithelial cells are considered a possible primary 
source for viral replication [63] as evidenced by the presence of viral antigens and/or DNA in 
respiratory, intestinal and renal epithelia of infected pigs, and hepatocytes as well as in 
cardiomyocytes of foetuses  [80, 124, 135]. The general consensus is that virus laden 
macrophages and DCs serve as the mode of systemic dissemination [63]. PMWS affected pigs 
have elevated PCV2 antibody titers but lack virus neutralizing antibodies (VNA) and cell-
mediated immunity (CMI) [134, 136-138], which explain the reasons for uncontrolled viremia 
leading to PMWS development. 
 The typical microscopic lesions observed in natural PMWS-affected pigs include 
extensive and severe depletion of both B and T cell regions of lymphoid tissues and their 
replacement by infiltrating viral laden histiocytes, macrophages and follicular dendritic cells 
(FDC), the formation of giant cells in lymphoid organs, thymic atrophy, granulomatous hepatitis 
with hepatocyte necrosis, interstitial pneumonia, interstitial granulomatous enteritis and 
granulomatous nephritis [39, 125]. In contrast, in subclinical infections in gnotobiotic and 
conventional pigs there is increased cellularity and germinal centre development in lymph nodes 
and lympho-histiocytic infiltration in liver, heart and kidney [63, 125]. The transition from 
subclinical infection to clinical disease is accompanied by the accumulation of large amounts of 
viral antigen in infiltrating mononuclear cells and the disappearance of germinal centres [63]. 
However, in both in vitro [62, 139] and animal experiments [63] there was no evidence for PCV2 
replication in macrophage and DCs. It is likely that progressive accumulation of viral antigens in 
these cells occurs as the result of phagocytosis [63]. Uptake of viral antigens can also be 
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enhanced by non-neutralizing antibodies [140]. Infectivity of the virus persists for a long period 
of time [61, 62] as a consequence to its ability to inhibit cellular endosomal maturation pathway 
[61]. The viral load in lymphoid tissues is positively correlated with the severity of lesions and 
clinical disease [28, 124, 125]. A similar correlation exists between viral load in the inguinal 
lymph node and the absence of PCV2 neutralizing antibody and CMI response to the virus [134, 
137]. Severe lesions in PMWS are associated with co-infections such as PRRSV, swine 
influenza and Mycoplasma hypopneumoniae [120].  
 The hemogram of PMWS-affected conventional pigs shows lymphopenia, neutrophilia 
and monocytosis, while the total leukocyte number remains within normal range. Lymphocyte 
and neutrophil counts are 30-40% and 60-70% respectively, almost the reverse of a normal 
hemogram. Both T and B lymphocyte counts are significantly depressed [138, 141-144]. 
However, affected pigs are not under general immune suppression as demonstrated by the 
persistence of PCV2 antibody titers [138] and the ability to mount humoral responses to 
unrelated antigens such as KLH in infected gnotobiotic pigs [124].  
 Analysis of cytokine mRNAs expression pattern in a range of lymph tissues provided a 
likely explanation for the altered immune responses in PMWS affected pigs [138]. Darwich et al 
(2003) showed significantly reduced expression of mRNA for IL-2, IL-4, IL-10, IL-12 and IFN-γ 
in inguinal lymph node and spleen, and increased IL-10 mRNA in the thymus compared to 
healthy pigs [138]. Similarly, peripheral blood mononuclear cells (PBMC) isolated either from 
PMWS affected pigs or healthy pigs exposed to PCV2 did not express IL-2, IFN-γ and IL-4 upon 
stimulation with either T cell mitogen (PHA) or staphylococcal enterotoxin B (SEB) super 
antigen [145], indicating a direct association between exposure to PCV2 and altered cytokine 
expression in lymph tissues. Further, plasmacytoid DC (natural interferon producing cells) 
incubated with PCV2 failed to respond to cytosine-phosphate-guanine dinucleotide (CpG) by 
upregulating MHC class II and CD80/86 costimulatory molecules and resulting in inhibition of 
TNF-α and IFN-α production required for myeloid DC (mDC) maturation, thereby affecting 
recognition of viral and bacterial antigens [139]. Virus neutralizing antibodies (VNA) are epitope 
specific [146]. VNA titer and their affinity depend upon multiple factors, including host genetics, 
nature of the viral epitope, duration of antigen exposure and the antibody isotype [147]. Impaired 
generation of VNA and CMI in PMWS affected pigs appears to be a consequence of 
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deregulation of immune functions by PCV2. The sequel to this is the enhancement of PCV2 
replication and vulnerability to co-pathogens. This suggestion was supported by the finding that 
vaccinated pigs developed VNA and CMI, and abrogated PCV2 viremia and co-infections [60, 
148, 149]. 
 Altered cytokine expression and impaired DC function caused by PCV2 also suggests a 
possible mechanism for the depletion of lymphocytes in lymph tissues in PMWS affected pigs. 
Clonal deletion of T lymphocytes is described subsequent to prolonged and overwhelming 
antigen stimulation by virus laden macrophages and DCs in the absence of co-stimulatory 
signals, i.e., expression of cytokines as occurs in PMWS affected pigs [150, 151]. This 
possibility is more convincing since findings of in vitro [61] and most of animal experiments [28, 
39, 63, 124], with a few exceptions [152, 153], are in agreement that lymphocytes do not permit 
PCV2 infection. Therefore, viral replication-associated damage to lymphocytes is unlikely. 
Further, the finding that lymphoid depletion was a result of decreased cell proliferation rather 
than increased apoptosis [154] strengthens the former explanation. 
 The mechanism of reproduction of PMWS in gnotobiotic pigs by immune stimulation 
[38] is likely mediated by induction of proliferation of cells that are minimally permissive to 
PCV2 [63]. This explanation is based on the finding that PCV2 replication is dependent  on 
cellular expression of DNA polymerases during the S phase of the cell cycle [76]. Immune 
stimulation also generates non-specific antibodies which can enhance viral uptake by 
macrophages and DCs [140], leading to increased lymphoid tissue viral load resulting in 
impaired immune functions. Antibody mediated enhancement of cellular uptake of viruses, 
thereby facilitating their replication and leading to augmentation of disease severity was 
described in the pathogenesis of diseases such as PRRSV, Dengue Fever and importantly in 
PDNS [140, 155-157]. The increased severity of lesions and clinical outcome because of co-
pathogens [37, 39, 75, 118] can also be explained by both of these mechanisms, i.e., induction of 
proliferation of viral permissive cells and generation of non-specific antibodies. In summary, the 
principal characteristics of PCV2 pathogenesis are lymphoid depletion and impaired generation 
of VNA and CMI, leading to uncontrolled viral replication. 
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1.3.13. Likely mechanism of wasting in PMWS affected pigs 
Wasting is a characteristic clinical feature of PMWS and affected pigs loose both muscle 
mass and fat deposits [158, 159]. Multiple mechanisms may be involved in any wasting 
syndrome. However, all the mechanisms collectively lead to a negative energy balance either by 
lower energy intake, lower feed conversion rate [158], as reported in PMWS, or increased 
metabolism. One of the possible mechanisms of loss of muscle mass and fat deposits is through 
systemic elaboration of proinflammatory cytokines, as observed in natural PMWS affected pigs 
[160].    
 Pro-inflammatory cytokines such as TNF-α and IL-1 act on the hypothalamus and cause 
fever and anorexia [161]. Anorexia causes less food intake while fever increases heart and 
metabolic rates. Pro-inflammatory cytokines induce lipolysis and oxidation of fat deposits, and 
stimulate the release of cortisol and catecholamines from the adrenal gland which increases the 
metabolic rate [162], resulting in increased energy consumption. Affected pigs suffer from 
jaundice and diarrhea  [114] suggesting that impaired digestion and absorption of nutrients 
contributing to lower energy intake. Loss of muscle mass is attributed to increased protein 
catabolism, as evidenced by elevated  blood urea levels in affected pigs [163], or to impaired 
synthesis mediated by pro-inflammatory cytokines such as TNF-α, IL-1β, IL-2, IFN-γ and IL-6 
[164-168].   
 The mechanism of action of the pro-inflammatory cytokines is through inhibition of an 
anabolic hormone, insulin-like growth factor 1 (IGF-1). This hormone is required in protein 
synthesis in skeletal muscle. Pro-inflammatory cytokines can inhibit the synthesis of this 
hormone at the transcriptional level or through the growth hormone axis by inhibiting 
stimulatory receptors on hepatocytes for growth hormone (GH) [167] . Elevated IGF binding 
protein-1 is also associated with a decrease in the rate of muscle mass reduction in wasting 
disease situations [167]. These cytokines can also exert direct effects on muscle protein synthesis 
by activating nuclear transcription factor (NF-κB). TNF-α and IFN-γ act synergistically to inhibit 
mRNA synthesis for myosin heavy chain. Cytokines also activate ubiquitin, a 76 aa proteolytic 
polypeptide responsible for muscle degradation [162]. In summary, one of the likely mechanisms 
of wasting in PMWS affected pigs is mediated by pro-inflammatory cytokines. 
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1.3.14. Economic impact of PCV2 infections 
The economic losses attributed to PCV2 infections result from increased mortality and 
culling, low market value for stunted pigs, reduced production parameters including lower feed 
conversion and average daily weight gain, poor reproductive performance including reduced 
number of live born and weaned piglets per litter, weaned piglets/productive sow/year and 
weaning-to-next heat interval, and the treatment, labour and veterinary intervention costs [113, 
120, 159, 169, 170].  
1.3.15. PCV2 control strategies 
 Control strategies for PCVAD are two-fold: vaccination and improved management 
practices.  
1.3.15.1. Improved management practices 
 An important element of combating PCV2 infection is minimizing on-farm infective and 
non-infective co-factors [108]. Co-pathogens such as PPV, PRRSV, M. hypopneumoniae and 
swine influenza exacerbate the severity of PCV2 induced lesions and cause explosive outbreaks, 
therefore, control of these infections is a primary focus in minimizing losses due to PCVAD [75, 
115, 117, 118, 120]. 
 The major goals include minimizing pig-to-pig contact and improved hygiene and 
nutrition [113, 171-173]. Pig-to-pig direct contact is identified as a potential means of viral 
spread in a herd while indirect contact through needles, surgical instruments, manure or people 
are documented as other possible means of spreading viruses [173]. Establishing solid partitions 
between pens and adopting all-in,all-out systems across the farm are recommended to reduce 
pig-to-pig contact [173]. The quarantine of purchased pigs is aimed at preventing the 
introduction of new infections. Thorough cleaning and disinfection procedures using an effective 
virocide, eg., Virkon (ANTEC® BIOSENTRY® Windham Road Chilton Industrial Estate 
Sudbury Suffolk, CO19 2XD United Kingdom), and good hygiene measures including regular 
changing of boots and clothes, stopping teeth clipping, prompt removal of sick and dead pigs, 
proper disposal of dead pigs are recommended to curb the spread of infection within herds/farms. 
Good colostrum management, i.e., adequate colostrums intake within 24 h of farrowing, 
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increased access to nutritious feed and disinfected water, improved temperature, ventilation and 
air quality and reduced pen size are measures aimed at improving health status and reducing the 
stress imposed upon the pigs.   
1.3.15.2. PCV2 vaccines   
 Currently, there are four commercial PCV2 vaccines available in Canada [96]; 
Circovac® by Merial Canada Inc. (20000 Clark Graham, Baie d’Urfé Québec, H9X 4B6) 
containing the whole virus, Suvaxyn® PCV2 One Dose by Fort Dodge Animal Health (P.O. Box 
25945Overland Park, KS, USA) [174] containing PCV1 engineered to express PCV2-Cap 
replacing its own capsid, Circumvent
TM
 PCV by Intervet Canada Corp (16750 route 
Transcanadienne Kirkland, Quebec, H9H 4M7) [60] and CircoFLEX
® 
by Boehringer Ingelheim 
Canada Ltd. (5180 South Service Road, Burlington, Ontario, L7L 5H4) [149] containing PCV2-
Cap expressed through a Baculovirus vector. All these vaccines contain inactivated PCV2-Cap 
as the vaccine antigen and, an adjuvant was incorporated except for Suvaxyn®. Circovac® is 
intended for sow vaccination; the primary vaccination is given intramuscularly at least 2 weeks 
before mating and the secondary at least 2-4 weeks before farrowing. Suvaxyn® PCV2 One 
Dose is administered intramuscularly once to healthy pigs 4 weeks and older. Circumvent
TM
 
PCV is recommended to be administered twice intramuscularly, 3 weeks apart to healthy pigs 3 
weeks and older.  CircoFLEX
®
 is a single dose vaccine administered intramuscularly to healthy 
pigs 3 weeks and older [96].  
 There are two recommended vaccination strategies. Circovac® is recommended to be 
given to sows, relying on the protective effects of passive transfer of maternal immunity to 
young piglets. The other three vaccines target piglets; primary immunization is recommended at 
3-4 weeks of age to induce active immune responses prior to the anticipated expected high risk 
period.  In one study [175], mortality rate up to finisher age (~19-22 weeks) were compared 
among four groups of pigs i.e., i. immunized through sow vaccination (passive immunization) 
ii.& iii immunized at young age (active immunization) with two different PCV2 vaccines 
designated A & B and iv. non-immunized controls. There was no difference in mortality rate 
between non-vaccinated pigs (10.7%) compared to pigs born to vaccinated sows (10.4%). 
However, piglets vaccinated at a young age had significantly lower mortality 3.9% and 3.1 % for 
vaccine A and B, respectively, favouring piglet vaccination over sow vaccination. PCV2 
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vaccines were shown to induce both humoral and cellular immunity and, thereby, reduce PCV2 
viremia, co-infections, morbidity and mortality rates, and improve production and reproductive 
performance [60, 120, 148, 149, 158, 159, 169, 170, 176-181]. 
1.4. BACTERIOPHAGES IN GENERAL  
 Bacteriophages are viruses that infect bacteria, and are the most abundant organisms on 
earth, totalling ~10
31
 [182]. They are ubiquitous in all natural environments and present in 
human and animal skin and in intestinal tracts [183, 184]. Bacteriophages constitute the order of 
Caudovirales, 96% of which are tailed, and are classified into 10 families based on their 
morphology and genome: single-stranded (ss) versus double stranded (ds), DNA versus RNA 
[183, 185]. The size of the phage genome can vary from 4-600 kb, carrying genes coding for 
DNA transcription, replication, packaging,  lysis and structural proteins including the head, tail 
and tail fibres [185]. There are two types of bacteriophages: virulent and temperate. 
Bacteriophages, through elements on the capsid, bind to specific receptors on the target 
bacterium, and inject their genome into the host cell. For virulent phages, the next steps of the 
life cycle are the initiation of viral replication followed by the production of progeny viruses. 
The life cycle of a temperate phage, such as lambda infecting E. coli., can be through one of two 
pathways: the viral genome can either integrate into the host genome (lysogeny), or undergo a 
replication cycle releasing progeny viruses by lysis of the host cell [186]. In contrast, filamentous 
phages do not lyse the bacterium but progeny viruses are released by extrusion from the cell 
membrane. Bacteriophages are incapable of binding and infecting organisms more complex than 
bacteria, because of differences in cell-surface molecules and intracellular machinery essential 
for phage replication [183]. Therefore, they do not replicate in eukaryotes and have been shown 
to be safe following oral administration in humans [187].  
 Bacteriophage lambda is a temperate phage infecting E. coli that contains linear ds DNA 
genome of 48.5 kb with single stranded termini of 12 nt (cohesive termini, cos termini) [188]. 
The lambda head is icosahedral, 55 nm in diameter and holds a 180 nm long, flexible, helical tail 
made of protein V arranged as a stacked disc tube terminating at the tail fibre made of J protein 
[189, 190]. The lambda genome is organized into functionally related clusters i.e., left-hand 
region: genes from Nu1 through J which control morphogenesis, central region: J through gam 
involved in gene regulation, establishment and maintenance of lysogeny and genetic 
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recombination, and right-hand region: gam through Rz which are essential in viral replication and 
lysis of the host cell [188]. Two clusters of genes, seven genes from A-F and 11 genes from Z-J, 
on the left-hand region govern the synthesis of the head and tail, respectively [191]. Lambda 
attaches to the bacterium using a specific receptor (LamB) and releases its DNA into the cell. 
Cos termini are base paired and formed closed circular DNA which serves as the template for 
transcription. DNA replication is initiated bidirectionally and then switches to rolling circle. The 
lytic cycle is completed in about 45 minutes and releases ~100 virus particles per infected cell 
[188].  
 The assembly of lambda particles is a multi-step process governed by both phage and 
host cell coded factors. In this sequential process, specificities for the assembly components arise 
by conformational changes [192]. If this process becomes defective, as in the generation of a 
mutant phage, all gene products, except one, are synthesized and, therefore, either a stable 
precursor lambda particle or a visibly different abortive particle is formed.  In the normal 
process, morphogenesis begins in the middle of the latent period while the precursor molecules 
are still being synthesized. At the initial step, the head begins to assemble under the control of 10 
phage coded  genes including genes A through F and Nu3; E and D are the two major structural 
proteins on the fully formed head [190]. First, a connector, a ring shaped structure is formed with 
12 monomers of B which interact with C and serve as the nucleation site for polymerization of E 
to form the prohead [193, 194]. Minor proteins B, C and Nu3 (sacffold protein) guide E in the 
proper assembly of the capsid protein shell, their absence leads to formation of a long tubular 
polyhead [190]. The prohead becomes competent in encapsidation of DNA after cleavage of the 
minor proteins. Replicating DNA made up of tandem repeats of mature ds DNA is packaged into 
the preformed prohead until it reaches its full capacity and cleaves from the extra long DNA 
molecule [190]. Protein A with its nuclease activity is responsible for this cleavage following the 
recognition of protruding 5′ single strand (cos terminal) of the encapsulated DNA. Proper 
assembly of the prohead is vital to produce progeny virus with a complete genome with double 
cos ends. Mutants with a defective prohead lead to accumulation of replicating DNA without 
completion of the packaging step [190]. During DNA packaging, the head expands ~20%  [193, 
195] and protein D is incorporated into the underlying prohead through its first 15 aa to stabilize 
the head [188], enabling packaging of full-length DNA. D-defective phages encapsidate only up 
to ~80% of complete genome [195], indicating that protein D plays a role in lambda 
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morphogenesis [188]. The mature lambda head consists of two major proteins, E and D, with 415 
and 405-420 copies, respectively. Protein E has a MW of 37.5 kDa [196] and is arranged in 
hexameric and pentameric capsomeres while D with MW ~11 kDa is folded into trimers [188] 
on each of 20 faces of lambda head.  To complete morphogenesis, W and F1 proteins prepare the 
head to join with the tail [190]. The tail binds to a corner of the head that had altered its 
symmetry being the site of either initiation, termination of head assembly or to which DNA ends 
are directed [190]. However, this binding process occurs in a manner ensuring release of phage 
DNA through the tail in the subsequent infection cycle.  
 Bacteriophages were studied mainly to understand molecular genetics of higher 
organisms [189, 197]. In addition to use of bacteriophage as therapeutic agents, knowledge of 
bacteriophage genetics paved the way to develop biologicals such as vaccines, gene therapy 
vehicles and diagnostic reagents. The discovery of phage encoded toxin genes, along with the 
analysis of bacterial genome sequence data, led to understanding the role bacteriophages play as 
important vehicles for horizontal transfer of virulent genes and, thereby, evolution and virulence 
of many pathogenic bacteria [198].  One category of bacterial virulence factors acquired through 
bacteriophages includes exotoxin genes such as diphtheria toxin in Corynebacterium diptheriae 
by β-phage, Shiga toxins in enterohemorrhagic E. coli O157:H7 by lambda phage and cholera 
toxin in Vibrio cholera by a filamentous phage [198-206]. Other types of virulence factors 
transferred through phages are effector proteins involved in invasion, such as type III secretary 
system in Salmonellae, enzymes such as hyaluronidase in Streptococci pyogenes, 
serum/phagocyte and antibiotic resistance factors and components necessary for bacterial 
adhesion and colonization in Streptococci mitis, causative agent for infective endocarditis [198, 
201].  
 Phage-mediated gene transfer occurs via two mechanisms: transduction and lysogenic 
conversion. It is estimated that such gene transfer events occur at a rate of up to 2 x 10
16
 per 
second [198]. In transduction, phages infecting a bacterium (transducing phages) pick up a 
fragment of host genome, package it into progeny virus and transfer it into another bacterium. In 
lysogenic conversion, certain temperate phages such as lambda, Mu and p2 phages incorporate 
their genome into the bacterial chromosome. In such an event, the bacterium and the 
incorporated phage genome is termed “lysogen” and “prophage” respectively. Gene transfer by 
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these mechanisms can occur between bacteria within the same or different species [198, 199].  
Lysogenic conversion allows the bacterium to be protected from lysis by a subsequent 
homologous phage infection (immunity) and, thereby, gains fitness in the environment compared 
to nonlysogenic counterparts [198]. Prophage is relatively stable and carries over to each 
daughter cell when the bacterium multiplies. However, certain stimuli such as UV radiation and 
antibiotics that damage bacterial DNA can induce prophage to initiate viral replication and 
produce progeny viruses. Certain bacterial pathogens exist in a less virulent, stage until prophage 
induction, and become increasingly virulent, with production of virulent factors since expression 
of virulent genes is regulated as part of phage life cycle [201]. Released phage carrying virulent 
genes can subsequently infect other resident bacteria leading to amplification of the pathogenic 
effect. The spread of certain diseases, such as cholera, is reported to be due to the dissemination 
of toxigenic phage rather than bacterium itself [205].          
 The ability of lambda phage to switch between lytic and lysogenic pathways is reported 
to be partly attributed to the manner of its genomic organization, which ensures a typical cascade 
of their expression in the order of early, delayed early, and late genes [207]. Repression of early 
phage promoter genes prevents expression of late lytic genes and arrests in lysogenic state. This 
repression is carried out by the expression of CI protein which binds to upstream phage 
regulatory genes and prevents prophage from entering into the lytic pathway. Conversely, 
inactivation of CI triggers the expression of genes necessary for producing progeny virus and 
lysis of host cell [207]. Therefore, lambda mutant containing temperature sensitive CI can be 
used to regulate expression of phage proteins by thermal induction. Lysogen can also 
spontaneously loose the prophage in a process referred to as “curing”.  
 In order to use bacteriophages in biotechnology applications, the kinetics and fate of 
bacteriophages in biological systems were studied in in vitro experiments [208, 209] and in 
laboratory animals inoculated through intraperitonial, intramuscular and intravenous routes [210, 
211]. A study using germ-free mice revealed the spleen had the highest phage titer at 3 hpi, 
irrespective of route of administration, and that titer was maintained for a period up to 7 days 
although phage titers declined to zero in blood by 48 hpi [208]. Bacteriophages, being particulate 
antigen, were reported to be rapidly removed by phagocytes in organs of the reticuloendothelial 
system (RES) including liver and spleen [208, 210]. Persistence of viable phages for long periods 
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of time in spleen was suggested to be due to spleen’s ability to capture antigen through a non-
destructive process, ensuring a source of viable phage for  immune stimulation [208] and for 
therapeutic effect [212].  The advantages of using bacteriophages in therapeutic and 
biotechnology applications are reported to include the feasibility of producing them rapidly and 
economically in large-scale, host specificity, safety, stability in a wide range of pH and 
temperatures, ability to target antigen presenting cells (APC) and their natural adjuvant activity 
thereby inducing both cellular and humoral immunity [210, 213-216].   
1.5. BACTERIOPHAGE TECHNOLOGY APPLICATIONS IN VETERINARY MEDICINE 
1.5.1. PHAGE THERAPY 
 With the increase in incidents of emerging antibiotic resistant pathogenic bacteria, there 
is a renewed interest in the use of bacteriophages as a therapeutic means in livestock, aquaculture 
and agriculture industries [186, 212, 217-226]. Important and successful veterinary applications 
include controlling diarrhoea due to E. coli in cattle and pigs and minimizing shedding of food 
borne pathogens such as E. coli O157:H7, Campylobacter and Salmonella by cattle and poultry. 
Advantages of phage therapy over the use of antibiotics include host specificity, relatively low 
cost and the phage being a viable agent replicating in the host and, therefore, exert an amplifying 
therapeutic effect [222]. Examples of therapeutic phage applications in veterinary medicine are 
described below.  
Cattle: 
 Young calves aged 6-12 hr separately infected with six different nonlysogenic 
enteropathogenic K
+
 E. coli strains at a dose of 10
9
 per animal were protected from otherwise 
developing fatal diarrhoea by oral administration of 10
5
 previously characterized bacteriophages. 
Protection was observed either with a dose of 10
5 
or 10
2
 phage treatment given 6 hr or 10 min 
prior to E. coli infection, respectively. Calves had significantly reduced bacterial counts in the 
faeces. On testing practical and convenient methods of phage treatment, protection was shown 
when calves were allowed to feed on litter sprayed with an aqueous solution of phage 
preparation 3 hr prior to E. coli infection. Similarly, six calves orally infected with a mixture of 
E. coli strains were protected from death by exposing them to a cocktail containing six virulent 
phages each specific for the respective bacterium [226]. In a similar study, five 6-month old 
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calves experimentally infected with E. coli O157:H7 had 1.5 log reduction in fecal bacterial 
shedding following rectal administration of a mixture of two lytic bacteriophages at a dose of ~ 8 
X 10
10
 pfu per animal per day combined with oral treatment by phage added to the drinking 
water to a final concentration of 5 x 10
5
 pfu/ml for 4 days [217].  
 Purified Staphylococcus aureus endolysin expressed in E. coli using a bacteriophage gene 
construct showed lysis of the bacterium in vito [224]. To test the efficacy of bacteriophage 
treatment in mastitis, healthy cows with subclinical Staphylococcus aureus mastitis were 
administered an intramammary infusion of 1.25 x 10
11
 pfu virulent phage per quarter per day for 
5 days. Milk samples collected weekly for 4 weeks after treatment were tested for S. aureus by 
culture. Cure, defined as negative bacterial isolation at any point of sampling, was achieved in 
only 16.7% of treated quarters and was not significantly different from the controls.  The lack of 
therapeutic effect was attributed to inactivation of phage by influx of  inflammatory cells and 
inhibition of phage activity by milk whey [221].   
Pigs: 
 Three-week old weaned pigs treated with a cocktail of six different lytic phages at10
10
 
pfu/animal following oral inoculation with ~10
10
 pfu enterotoxigenic E. coli (ETEC) 
O149:H10:F4 were protected from diarrhoea and associated weight loss. Similarly, infected pigs 
treated with a mixture of two phages, 3 times at 6h intervals 24 h after developing diarrhoea, had 
a significant improvement in weight change and decreased severity and duration of diarrhoea 
indicating phages can effectively be used for both preventive and therapeutic purposes [219].    
Poultry: 
 Three-week old SPF chickens with septicaemia and meningitis induced by intramuscular 
or intracranial administered E. coli O18:K1:H7 were protected when treated intramuscularly with 
10
8
 pfu of lytic bactriophage simultaneously or 8 h prior to infection [212]. In a similar study, 
10-day old Campylobacter and Salmonella free broiler chickens experimentally infected with  C. 
jejuni were treated with host specific bacteriophage orally at 10
9-10
 pfu per bird per day for 10 
days until 4 days prior (preventive purpose) to bacterial challenge or for 5 days starting at 6 days 
after bacterial inoculation (therapeutic purpose). Caeca collected at 3-day intervals following 
phage therapy revealed success of both preventive and therapeutic treatment as  bacterial 
colonization was reduced by 1 log over a period of 30 days compared to controls [220].  
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 Although, there are successful therapeutic applications of bacteriophages, phage therapy 
is not yet a widely accepted method of treatment in medical and veterinary sciences. The reasons 
attributed to this situation include unreliable and inconsistent early phage therapy trials, lack of 
control studies published in peer reviewed journals, difficulties in maintaining viability of phages 
in biological systems due to phagocytosis, the presence of inhibitory substance such as pus and 
necrotic materials at the target site, the potential for endotoxic shock as a result of releasing large 
quantities of endotoxins from lysed gram-negative bacteria and the difficulties obtaining 
intellectual property rights  [214, 224].     
 
1.5.2. BACTERIOPHAGE DISPLAY SYSTEMS 
 Bacteriophage display is a versatile technique enabling the display of a wide variety of 
foreign peptides for multiple applications including antibody engineering and discovery, protein 
engineering technologies such as random and site directed mutagenesis, for the detection of 
biological threat agents, gene therapy, drug design, chemotherapy and for the development of 
diagnostic reagents and vaccines [188, 189]. Three bacteriophage display systems including 
filamentous phages [227-229], T4 [230] and lambda bacteriophages [5] have been used to 
develop vaccines. In the filamentous phage M13 display system, major coat protein (pVlll, 2700 
copies) and minor coat protein (plll, 5 copies) are most widely used as fusion partners. 
Filamentous phages do not lyse the host cell. Hence, peptides intended to display must traverse 
across the host cell membrane which causes difficulties in displaying some foreign peptides. 
Further, display density i.e., number of peptides that are displayed per phage particle, is very low 
in this system and the size of the peptide is limited to six to eight amino acids, as larger peptides 
interfered with phage assembly [189]. These difficulties are avoided by using lytic phages such 
as T4 and lambda. Small outer capsid protein (SOC, 810 copies) and highly immunogenic outer 
capsid protein (HOC, 155 copies) are used in the T4 display system. Both HOC and SOC 
proteins are easily accessible and nonessential for phage morphogenesis, viability or infection 
[230, 231]. Phage lambda is reported to be a superior display system compared to filamentous 
and T4 bacteriophages in terms of variety, size and number of peptide copies displayable per 
particle (display density), without affecting phage morphogenesis [188, 197, 232-237].  
 High display density is critical in certain applications such as identification of ligands 
binding to specific antibodies to develop diagnostic assays and therapeutic vaccines for diseases 
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such as cancer, autoimmune diseases and age related conditions where antibody titers are 
generally very low, and for detecting biological threat agents where efficiency of detecting even 
few organisms is vital. For drug and gene delivery and especially for vaccine delivery vehicles it 
is preferable if the phage is entirely covered with immunogenic peptides [189]. Initially, peptides 
were fused to lambda major tail protein V [236]. This display system yielded a low number of 
fused molecules per phage particle [188]. Later, a high level of expression was achieved by 
fusing peptides to lambda head D protein [232].  Both the N and C termini of the protein D are 
accessible for fusion peptides since they are not at the trimmer interaction face and do not 
interact with protein E [188]. A higher display density was obtained by fusing peptides to C-
terminal (88.4%) compared to N-terminal (~50%) [238].  
1.5. 3. BACTERIOPHAGE VACCINES 
1.5.3.1. Phage display vaccines 
 In an in vitro experiment to demonstrate filamentous bacteriophage as an antigen delivery 
system, antigen presenting cells pulsed with phage displaying a HIV-1 T-cell epitope fused at the 
N-terminus of pVIII major coat protein demonstrated antigen specific T cell proliferation. 
Sequence analysis of purified phage particles revealed only 10% of the pVIII copies available for 
fusing peptides was actually used up in this experiment [239]. 
 Mice orally administered filamentous M13 phage displaying mimotopes, i.e., peptides 
that mimic specific ligands of human hepatitis B surface antigen (HBsAg), at a dose of 10
12
 
particles per animal had an immune response only to phage coat proteins, without any 
measurable antigen-specific response by ELISA. The failed response to the target antigen was 
attributed to either inactivation by acidity in the stomach or to an inadequate amount of displayed 
peptides on the phage particles [227]. In contrast, mice immunized intraperitonially three times 
at 2 weeks intervals, with 1 mg of purified recombinant filamentous bacteriophage displaying 
protective epitopes of human respiratory syncytial virus (HRSV) showed antigen specific 
immune response and conferred complete protection following a lethal challenge dose [228].       
 Four types of recombinant filamentous M13 phages, each displaying one of four 
protective epitopes of Taenia solium fused to pIII protein were produced in bulk, inactivated and 
sterilized by autoclaving 30 min at 121 
o
C. In a placebo-control vaccine experiment, a phage 
preparation constituted with a cocktail of 10
12
 particles from each display product was 
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administered subcutaneously twice at monthly intervals to 3-4 month old piglets raised under 
field conditions in a porcine cysticercosis endemic area in Mexico. Pigs were examined for 
lesions of tongue cysticercosis 3-5 months after vaccination or for the presence of parasites in 
internal organs at slaughter. Tongue lesions were fewer in vaccinated pigs (3.9%) compared to 
the control group (14.2%), demonstrating 70% vaccine efficacy. The vaccine also reduced the 
number of infected pigs and their parasitic load resulting in a decrease in disease prevalence by 
54.2% [229].  
 Recombinant T4 phage displaying foot-and-mouth disease virus (FMDV) full length 
capsid precursor polyproteins, namely P1 and proteinase 3C fused to SOC protein, was produced 
by inserting genes coding for P1 and 3C separately into the phage genome by homologous 
recombination; T4 phage infecting E. coli transformed with shuttle plasmid containing P1 or C3 
cDNAs. Mice dually immunized with four doses of recombinant phages at 2 week intervals by 
intraperitonial (10
9
 particles per mouse) or oral routes (10
7-8
 particles per mouse) showed 100% 
protection following a lethal dose of FMDV [230]. In a similar study, both SOC and HOC 
proteins of T4 phage were fused with ProA from Neisseria meningitidis individually or dually on 
a single phage particle. Mice immunized with these recombinant peptides showed 
seroconversion to respective peptides with higher titers against T4proA-Hoc compared to 
T4proA-Soc [231], proving HOC a better fusion partner compared to SOC in terms of inducing 
immunity.  
1.5.3.2. Phage DNA vaccines 
 Hepatitis B surface antigen and eukaryotic promoter cloned into bacteriophage lambda, 
λ-HBsAg was injected four times into rabbits intramuscularly at a dose of 4 x 1010 particles per 
animal at 0, 9, 15 and 27 weeks. An anti-HBsAg immune response was shown in test animals 
compared to controls receiving recombinant HBsAg protein [240].  
 Although, there are number of requirements to be fulfilled prior to phage vaccine 
becoming widely practiced, one important issue to pharmaceutical companies is obtaining 
intellectual property rights [214].  
 
1.5.4. BACTERIOPHAGE DIAGNOSTIC REAGENTS 
 A rapid and sensitive E. coli detection system was developed using biotinylated lambda 
phage. Temperature sensitive lambda lysogen was inserted with DNA coding for biotin binding 
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peptide (BBP) so that thermal induction resulted in generation of biotinylated lambda progeny 
virus particles displaying BBP fused to D protein (λgpD:bio). Biotinylation of BBP occurred 
naturally in the host bacterium using its own BirA enzyme. For the test, λgpD:bio were collected 
and added to a test sample that could contain E. coli together with streptavidin conjugated 
quantum dots (colloidal crystals a few nanometers in diameter). E. coli in the sample (target 
cells) were labelled with λgpD:bio-streptavidin QD complexes following an incubation step. 
Importantly, this technique used a mutant lambda phage that is incapable of lysing target E. coli 
cells. The sample was then analysed by flow and image-based cytometry to precisely detect and 
quantify the number of target E. coli cells. This technique is considered to be highly valuable in 
detecting slow growing or highly pathogenic bacteria such as Mycobacterium and Bacillus 
anthracis for which conventional diagnostic methods are either less efficient or require rigorous 
bio-safety regulations. This technology has the potential to detect different bacterial species 
simultaneously in a sample and is adaptable to field use due to broad environmental and storage 
stability of phage [241, 242].       
 A methodology was developed to detect viable Bacillus anthracis [243]. In this 
technique, gamma phage which replicates only in the presence of live Bacillus anthracis is 
detected using   real-time PCR (RT-PCR) with 98% specificity. This technique is claimed to be 
quicker than the currently CDC approved standard protocol which requires isolation of colonies 
of Bacillus anthracis from an overnight culture and testing them for bacterium-specific capsular 
protein and plate lysis assay with gamma phage. Further, positive results in the new technique 
are indicative of the presence of viable Bacillus anthracis compared to its detection based on 
RT-PCR set to amplify bacterial DNA which detects nonviable bacteria as well.     
 In a similar approach, an assay was developed to detect Mycobacterium avium subsp. 
paratuberculosis in cow’s milk [244]. Milk samples were incubated with the Mycobacterium 
phage and then plated on a lawn of amplifying host, M. smegatis. The resultant plaque was 
indicative of the presence of one of the four test phage sensitive Mycobacterium species. Positive 
samples are then tested by RT-PCR to confirm the presence of target species, Mycobacterium 
avium subsp. paratuberculosis using specific primers. 
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HYPOTHESIS 
1. The parenteral administration of a prototype  adjuvanted PCV2 vaccine can override        
maternally-derived PCV2 antibodies. 
2. A lambda display PCV2 vaccine can overcome some of the drawbacks associated with 
commercial PCV2 vaccines. 
OBJECTIVES  
Maternal antibody interference to the induction of anti-PCV2 immune response is a constant 
concern when piglets are vaccinated at an early age against PCV2 associated diseases. My 
objective was to determine if the parenteral administration of a prototype, adjuvanted, PCV2 
vaccine could override maternally-derived PCV2 antibodies, and induce active immunity in 
seropositive piglets.  
There are few PCV2 vaccines available in Canada. All of them are killed vaccines likely 
containing varying amounts of spurious proteins that can cause adverse injection site reactions. 
The inactivation process involved in producing killed vaccines can inadverantly alter protective 
antigen epitopes and compromises vaccine efficacy. Production of these vaccines either by 
propagating PCV2 in cell cultures or expressing recombinant viral proteins in vitro is expensive.  
I wished to test a new lambda display PCV2 vaccine candidate that is very economical, highly 
immunogenic, and contains intact protective epitopes. First, I needed to determine if 
conventional pigs contain pre-existing antibodies against bacteriophage lambda, in order to 
ensure that the phage vaccine can be administered into pigs without the risk of suppressing the 
target-vaccine antigen-specific immune response. Secondly, I wished to prepare and characterize 
the vaccine candidate particles displaying immunodominant regions of PCV2Cap fused to 
lambda head protein D (LDP-D-CAP). Thirdly, it was essential to evaluate immunogenicity of 
the vaccine in conventional pigs. Finally, I wished to prepare and characterize two alternative 
lambda display preparations, LDP-D-FLAG and LDP-D-GFP and, displaying the FLAG tag and 
the green fluorescent protein respectively.   
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CHAPTER 2: EFFICACY OF PARENTERAL VACCINATION AGAINST PORCINE   
  CIRCOVIRUS 2 (PCV2) IN SEROPOSITIVE PIGLETS  
1. Introduction 
Porcine Circovirus 2 (PCV2) are small, non-enveloped, single stranded DNA viruses 
[22]. PCV2 has been incriminated as a necessary cause for postweaning multi-systemic wasting 
syndrome (PMWS) [39]. This disease develops in piglets typically between 8-16 weeks of age, 
manifesting clinical signs including progressive emaciation, dyspnoea and enlarged superficial 
lymph nodes and results in a high case fatality rate [114]. PCV2 is also associated with a number 
of other diseases such as porcine dermatopathy nephropathy syndrome [126], reproductive 
disorders [130],  proliferative and necrotizing pneumonia [131], and porcine respiratory disease 
complex [129]. Recently, a sharp increase in PCV2-associated deaths was reported in Canada 
[53, 245]. PCV2 is a very stable virus [72] and is ubiquitous in the swine population [114], 
making it very difficult to eradicate. Vaccination represents an attractive means to control the 
effects of this endemic infection and has been shown to be an effective strategy in controlling 
PCV2-associated diseases in some studies [60, 149, 246-248]. Several commercial PCV2 
vaccines are available in North America. There are two recommended vaccination strategies: 
vaccinating sows and relying on passive transfer of maternal immunity, or immunizing young 
piglets to induce an active immune response. Effectiveness of sow vaccination can be 
complicated by several factors. First, maternally-derived PCV2 antibodies (MDAs) are generally 
short-lived (3-4 months) [249] and would not last until the PMWS high risk period between 7-15 
weeks of age [114, 115]. Secondly, MDAs may confer only partial protection against such 
infections as PCV2 and rotavirus [133, 250].  Finally, MDAs possess virus neutralization 
capacity [251] but that alone may not be optimal or sufficient, since both humoral and cellular 
immunity may be essential in combating this viral infection.  Vaccination at a young age could 
be used as an alternative, or together with sow vaccination; however, the efficacy of piglet 
vaccination may be negatively affected by MDAs for PCV2 in such an approach. To address the 
potential limiting effects of passive immunity, we investigated if parenteral administration of a 
prototype adjuvanted PCV2 vaccine to piglets at an early age could override MDAs for PCV2 
and induce acquired immunity in young piglets.  
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2. Materials and methods 
2.1. Formulation of the vaccine 
  PCV2 vaccine antigen was prepared according to previously reported methods [72, 78]. 
The  amount of viral antigen and the total protein in the vaccine preparation was estimated by 
antigen capture ELISA [79, 84] and Bradford method [252], respectively. The LR4-incomplete 
oil-in-water adjuvant (Merial, ) was heated at 37
o
C for 10 min followed by 
stirring for 1 min before it was cooled rapidly to 4
o
C. The vaccine was diluted 1:1 with PBS 
(0.0036 M KCl, 0.0014 M KH2PO4, 0.136 M NaCl, 0.004 M Na2HPO4, pH 7.8) and maintained 
at 4
o
C until dispensed over 1 min into an equal amount of adjuvant that was being stirred slowly 
at 4
o
C. This vaccine formulation was stirred for an additional 1 min and stored at 4
o
C overnight. 
Similarly adjuvanted PCV-free PK-15 (Dulac) cell lysate served as the control. 
2.2. Preparation of challenge inocula 
2.2.1. Spleen tissue homogenate 
The viral inoculum for the initial challenge was prepared from a 10% (w/v) tissue 
homogenate of a spleen collected from an experimentally infected gnotobiotic pig. The 
homogenate was sonicated for 30 seconds at full power followed by centrifugation (BECKMAN 
COULTER, Avanti J-E, JA-17 rotor) at 12,000 rpm. Chloroform (5%, v/v) was added to the 
supernatant and mixed by constantly inverting the tube for 10 min at room temperature. The 
content was centrifuged at 2,000 rpm and the top layer removed from the chloroform. This was 
centrifuged (BECKMAN COULTER, Optima LE 80K, 70Ti rotor) at 30,000 rpm in order to 
pellet the virus. Pellets were suspended in PBS and filtered through a 0.2 µm filter.   
2.2.2. Tissue culture lysate  
PCV2 (Stoon 1010) was propagated in PCV-free PK-15 cells (Dulac) as described 
elsewhere [64, 76]. The medium covering the cell layer in tissue culture flasks (35ml/T175 flask) 
was removed, the cells were washed  twice with PBS and the medium was replaced with 
minimum essential medium (Invitrogen, Carlsbad, CA, USA) with no fetal calf serum or 
antibiotics added. Cells were then frozen and thawed 3X, sonicated for 30 seconds at full power, 
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centrifuged at 10,000 rpm and the supernatant collected and mixed with commercially available 
palatable syrup prior to feeding the pigs. 
2.3. Experimental design 
Twenty 1-week old piglets from four different litters were purchased from a farm where 
PCV2 vaccination was not practiced, identified individually, randomized into vaccinate (10) and 
control (10) groups based on their weight. They were in four different farrowing crates at the 
farm at primary vaccination at week 1 of age. Vaccinates were administered a dose of 200 µl of 
inactivated adjuvanted PCV2 vaccine intradermally using an injector gun (Biojector 2000, 
Bioject Inc. USA). Each dose of vaccine contained PCV2 antigen equivalent to 4.75 x 10
4
 50% 
tissue culture infective doses (TCID50). Control pigs were injected with 200 µl of adjuvanted 
uninfected PK-15 cell lysate. At week 3 of age, they were brought to the WCVM animal care 
facility, group housed in a 15.4 square meter pen, fed a commercial medicated diet until week 10 
of age and, thereafter, switched to nonmedicated pig grower ration. Water was supplied ad 
libitum. Vaccinates and controls were administered a booster dose of the vaccine and control 
preparation, respectively, at week 4 of age. Three weeks after the second treatment, both groups 
were challenged, initially by administering orally 2 ml of PCV2 inoculum, prepared from spleen 
tissue homogenate containing 1.6 x 10
5
 TCID50 of PCV2 per pig, followed by feeding inocula 
containing PCV2-infected PK-15 cell lysate and a fresh culture of Campylobactor coli and 
Helicobactor cerdo mixed with a commercially available syrup (Aunt Jemima Original syrup, 
Quaker Oats Company, Chicago, IL), delivering 3.6 x 10
3
 TCID50 of PCV2 per pig per day for 
next 3 days. Pigs were monitored visually for general health and clinical signs of PMWS during 
the experiment and euthanized by captive bolt at 3 weeks post-challenge. Gross lesions were 
assessed by a team of experts in this field who carried out the post-mortems. Inguinal, axillary, 
bronchial, mesenteric, gastric lymph nodes, thymus, tonsils, spleen, liver, ileum and bone 
marrow were collected in 10% buffered formalin for histopathology. Sera were collected prior to 
each immunization, challenge and euthanasia, i.e., at week 1, week 4, week 7, and week 10. The 
experimental protocol was approved by the University of Saskatchewan Animal Care and Supply 
committee (protocol number, 20050029). 
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2.4. Serology 
2.4.1. Antigen capture ELISA  
 Antigen capture ELISA was performed as previously described [79, 84] to measure the 
amount of PCV2 antigens in the vaccine preparation and the challenge inocula. A flat bottom 96-
well ELISA plate (Immunolon 4HBX, THERMO ELECTRON Corporation, milford, MA, USA) 
was coated with a monoclonal antibody (mAb, 2B1 F190) against PCV2 1002 isolate [79]  in 
volumes of 100 µl per well at a dilution of 1:1500 in coating buffer (0.05M Sodium carbonate, 
pH 9.2). The plate was incubated overnight at 4
o
C. The coating buffer was then removed and the 
plate was washed (4X) with PBS + 0.05% Tween20 (PBST). The test samples and a standard 
PCV2 capture ELISA antigen (Stoon 1010 pool 28) with known TCID50 were serially diluted 
(1:250, 1:500 etc) in PBST and 100 µL volumes of each dilution were added into duplicate 
wells. The plate was incubated 2h at 37
o
C. After a similar washing step, 100µL per well of anti-
PCV2 rabbit polyclonal antiserum was added at a dilution of 1:2500 in PBST and the plate was 
incubated for 1h at 37
o
C. The plate was washed (4X) with PBST, 100µL per well of biotinylated 
goat anti-rabbit (Invitrogen, Carisbad, CA, USA) was added at a dilution of 1:4000 in PBST and 
the plate incubated at 37
o
C for 1h. The plate was washed (4X) in PBST and 100 µl per well of 
Streptavidin-peroxidase conjugate (ABC reagent, Vector Laboratories Inc., Burlingame, CA, 
USA) diluted in PBST according to the manufacturer’s recommendation was added and the plate 
was incubated at 37
oC for 30 min. 3.3’, 5.5’-tetramethylbenzidine (TMB) substrate (KPL Inc., 
Gaithersburg, Maryland, USA) was added at 100 µl per well, after washing the plate (4X) with 
PBST. The reaction was stopped by adding 50 µl per well of 1M H2SO4 after 15 min of 
incubation at ambient temperature. The optical density of the solution in the wells of the plate 
was read at 450 nm. PCV2 antigen concentration in the test samples was calculated in terms of 
TCID50 based on the standard curve plotted using respective concentrations in the standard PCV2 
antigen dilutions.  
2.4.2. Competitive ELISA (cELISA) 
A competitive ELISA was employed to measure anti-PCV2 antibodies in pig sera as 
previously described [94]. The ELISA plate was coated with PCV2 antigen (PCV2 isolate # 
48285) 100 µl per well at a dilution of 1:200 in a coating buffer (0.05 M Sodium carbonate, pH 
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9.2). The plate was incubated overnight at 4
o
C.  The coating buffer was then removed and the 
plates were washed (4X) with PBS + 0.05% Tween20 (PBST). Each serum sample diluted at 
1:125 in PBST was added in volumes of 50 µl per well in quadruplicate (two adjacent rows and 
columns of the plate per sample) and incubated at 37
o
C for 45 min. Each plate included four 
wells each for blank (no serum, PBST only), negative and positive control sera. Without washing 
the plate, in alternative columns (2, 4, 6 etc.) monoclonal antibody (B12B6) was added to PCV2 
isolate 48285 at 1:100 in PBST in volumes of 50 µl per well while to the remaining columns (1, 
3, 5 etc.) only PBST in volumes of 50 µl per well. The plate was incubated at 37
o
C for 30 min, 
washed 4X with PBST and horse radish peroxidise (HRP)-conjugated goat anti-mouse antiserum 
(Invitrogen, Carisbad, CA, USA) at a dilution of 1:5000 in PBST containing 5% (v/v) goat serum 
(Invitrogen, Carisbad, CA, USA) added in volumes of 100 µl per well.  The plate was incubated 
at 37
o
C for 1h and washed 4X with PBST before addition of TMB substrate (KPL Inc., USA ) in 
volumes of 100 µl per well. Color development was stopped with 1M H2SO4 in volumes of 50 µl 
per well after incubation for 10 min at room temperature. The optical density of the substrate 
solution was read at 450 nm. Blank wells containing only the monoclonal antibody (mAb) 
without test sera represented a complete reaction (0% inhibition) while in wells containing both 
mAb and test sera containing PCV2 antibodies compete for the coated PCV2 antigen, hence, the 
reaction is inhibited. The percentage of inhibition was calculated for each sample as previously 
described [94]. 
2.5. Histology and Immunohistochemistry (IHC)  
Inguinal and gastric lymph nodes were fixed in 10% buffered formalin, embedded in 
paraffin, sectioned at 5μm and rabbit anti-PCV2 polyclonal antisera used to detect PCV2 
antigens by IHC [39]. H & E stained sections of left inguinal and gastric lymph nodes were 
examined for lymphoid depletion, lymphoid hyperplasia (follicle formation), germinal centre 
development, histiocytic hyperplasia and syncytial giant cell formation. The amount of PCV2 
antigens, detected by IHC, were evaluated without knowledge of the identity of the sample on a 
scale of 0 to 3+; 0=negative, 1+=minimal, 2+=moderate, and 3+=Extensive.   
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2.6. Statistical analyses 
The net change in cELISA values for individual pigs from primary vaccination to 
booster, challenge and 3 weeks post-challenge, respectively, as calculated by subtracting relevant 
individual animal cELISA values. The Wilcoxon Rank Sum test was used to test comparisons as 
data were not normally distributed. Comparisons with a P-value < 0.05 were considered 
significant. Statistical testing was done using a commercial software package (Statistix 8; 
Analytical Software, Tallahassee, Florida, USA). 
3. Results 
3.1. PCV2-specific antibody responses 
 Anti-PCV2 antibodies measured by cELISA in individual control (8) and vaccinated pigs 
(10) are presented in Figures 2.1 & 2.2, respectively. Though the vaccination trial began with ten 
pigs per group, one control pig was euthanized because of infectious arthritis and data for 
another control pig was not considered as it was mistakenly immunized at the booster 
vaccination. MDAs for PCV2 were not significantly different (> 80% inhibition in all pigs) 
between the two groups at 1 week of age. Antibody levels declined in control pigs until 
challenge at 7 weeks of age, whereupon antibodies increased in all piglets except for piglet # 14 
(Fig. 2.1). Among vaccinated piglets, there were two patterns of change in PCV2 antibodies; five 
of 10 pigs (sub group A) maintained a higher level of PCV2 antibodies (P = 0.008; Range: 70-
100% inhibition (Fig. 2.2) from week 1 to week 4 following primary vaccination compared to 
the remaining five pigs (sub group B) whose antibody levels decayed similarly to controls 
(Fig.2.1.). Only three of the pigs in sub group A (# 13, 28 and 30) maintained a high level of 
immunity following booster vaccination at 7 weeks of age and one of these pigs showed a 
decline in titer by week 10 (# 28).  cELISA values for vaccinates as an overall group were not 
significantly different from controls at any time period. All but two immunized pigs (# 18 & 28) 
mounted an immune response to challenge (i.e., week 10, Fig. 2.1 & 2.2). Importantly, this 
response to challenge included 2/3 of the vaccinates (pig # 13 and 30) that maintained high 
cELISA titers (~80% inhibition) at 7 week of age. 
Net decrease in cELISA value, compared after completion of vaccination (Week 1 to 
Week7) was less in vaccinates compared to controls (P = 0.04; Fig. 2.3).  
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3.2. Clinical signs and gross lesions 
 None of the controls or vaccinated pigs had clinical signs of PMWS during the 
experiment or gross lesions at post-mortem examination. 
3.3. Histology and IHC  
All the controls and vaccinates had microscopic lesions including lymphoid hyperplasia, 
germinal centre development and histiocytic hyperplasia (Table 2.1). However, no pigs had 
lymphoid depletion and syncytial giant cell formation, two characteristic microscopic lesions of 
clinical PMWS. By IHC staining, PCV2 antigens in left inguinal and gastric lymph nodes were 
detected in one and two of the eight controls, respectively (Table 2.2). The antigen staining 
intensity score was 1+ for all positive stains in a scale ranging from 0 to 3+. Among nine 
vaccinates tested, only one had  positive staining in the left inguinal lymph node with a score of 
2+ and three had scores of  1+, 2+ and 3+, respectively, in gastric lymph node. This finding 
suggests that there is no difference between controls and vaccinates in terms of proportion of 
PCV2 antigen positive pigs i.e., 1/8 and 1/9 of controls and vaccinates, respectively, positive in 
the left inguinal lymph node while 2/8 and 3/9 of controls and vaccinates, respectively, positive 
in the gastric lymph node. However, two of the vaccinates (#6 and 22) had higher intensity of 
staining in both left inguinal and gastric lymph nodes compared to that of controls.  
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Fig. 2.1 cELISA measuring anti-PCV2 immune responses in individual control pigs 
  receiving PCV2- uninfected PK 15 cell lysate mixed 1:1 with an adjuvant, twice 
  at 3-week intervals, followed by oral challenge with PCV2 inoculums. 
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Fig. 2.2  cELISA measuring anti-PCV2 immune responses in individual vaccinates 
  receiving inactivated PCV2- infected PK 15 cell lysate mixed 1:1 with an   
  adjuvant, twice at 3-week intervals, followed by oral challenge with PCV2  
   inoculums. 
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Fig. 2.3 Box and whisker plot for net change in cELISA values in controls and 
 vaccinates following primary vaccination (Week 1 to Week 4), booster (Week 1 
  to Week 7) and the challenge (Week 1 to Week 10). There was a significantly (P 
  < 0.05) smaller decline in cELISA PCV2 antibody levels in vaccinates compared 
  to controls following booster vaccination (Week 1 to Week 7). 
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Table 2.1 
Number of pigs with histological lesions in H & E stained sections   
 of left inguinal and gastric lymph nodes. 
Hitologic lesion  Controls (8)
a
 Vaccinates (9)
a
 
Lymphoid hyperplasia 8   9   
Histiocyte hyperplasia 8   9   
Germinal centres  8   9   
Lymphoid depletion  0   0   
Giant cells   0   0   
a
 Number of pigs assayed in each group. 
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Table 2.2   
Immunohistochemistry scores for the presence of PCV2 antigens in two lymph nodes.  
Pig ID  Group  Left inguinal  Gastric  
 3  Control   0  0       
5  Control   0  0 
      7  Control   0  0 
      9  Control   0  1+ 
    14  Control   0  0 
    21  Control   0  0 
    24  Control   0  0 
    26  Control  1+  1+ 
      2  Vaccinated  0  0 
      4  Vaccinated  0  0 
      6  Vaccinated  0  2+ 
    10  Vaccinated  0  0 
    13  Vaccinated  0  0 
    18  Vaccinated  0  0 
    19  Vaccinated  0  0 
    22  Vaccinated  2+  3+ 
    30  Vaccinated  0  1+   
0=No staining, 1+=Minimal, 2+=Moderate, 3+=Extensive  
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4. Discussion 
 As expected, given the endemicity of PCV2 infection in commercial swine herds [83, 
97], both controls and vaccinated piglets had equally high levels of MDAs for PCV2 prior to 
vaccination. Although individual animal’s responses to vaccination can vary [253], the reason for  
the two patterns of PCV2 antibody levels among the vaccinated group, i.e., sub groups A and B,  
following primary vaccination is not clear. To evaluate the immune response to vaccination in 
the pigs with maternally-derived antibodies, we compared the net change in cELISA values for 
vaccinates and controls at week 7, following the booster vaccination.  The decline in cELISA 
values in vaccinates was significantly less compared to controls indicating likely a positive effect 
of immunization.   
 The aim of this study was to investigate the efficacy of a parenterally administered PCV2 
vaccine in the presence of MDAs for PCV2. Possible reasons for the absence of remarkable 
effect of vaccination on PCV2 antibody titers in the vaccinated piglets include the inhibitory 
effect of high concentrations of MDAs and/or inadequate amount of vaccine antigen in the final 
preparation. Mechanisms by which high levels of MDAs can influence the efficacy of live 
attenuated vaccines include neutralization of the vaccine antigens and formation of 
MDAs:vaccine antigen complexes that could mask vaccine antigen specific epitopes, inhibition 
of B cell activation, or enhanced elimination by phagocyte cells [251, 254, 255]. Since an 
inactivated vaccine was  tested, formation of MDAs:antigen complexes is a more likely 
possibility for the retarded vaccine effect  observed in this study [256].  MDAs are known to 
interfere with humoral response while T cell priming may remain unaffected [251], although cell 
mediated immune responses following the challenge were not examined in the current study to 
provide evidence to this effect.  A key determinant of MDAs interference is the ratio of vaccine 
antigen: MDAs, therefore, increasing the vaccine antigen dose may circumvent this issue [255]. 
Both control and vaccinates, including those pigs with high anti-PCV2 antibody titers 
(pig # 13 and 30), responded to the challenge inocula that contained the larger amount of PCV2 
antigen. This observation demonstrated firstly, that the challenge dose was likely effective and 
secondly, that the inhibition of immune induction by pre-existing antibodies is reversible by 
modifying the antigen: antibody ratio, suggesting that improved immune responses may be 
achieved with increased antigenic mass in the vaccine. Piglets immunized at 4 and 7 weeks of 
42 
 
age with a recombinant pseudorabies virus expressing PCV2-Cap at a dose of 1 x 10
5
 TCID50 of 
PCV2 antigens per pig [257], compared to a dose of 4.75 x 10
4
 TCID50 per pig employed here in 
1-week-old piglets, reported a significant anti-PCV2 immune response. Another study examining 
the influence of MDAs on the efficacy of a PCV2 vaccine using 4-week-old piglets documented 
a significant reduction in microscopic lesions in lymphoid tissues and viremia in vaccinated pigs 
[148]. Together, these variable results suggest that the amount of MDAs as well as differences in 
vaccine formulation, including differences in adjuvants may determine the success of priming for 
PCV2-specific immunity in piglets with passive immunity. PCV2 isolates with different genetic 
makeup had shown cross protection against each other [60] and, therefore, the vaccine strain 
(data not shown) used in the present study could not have influenced the findings.     
We conducted a separate experiment (data not shown) with another group of pigs that 
were vaccinated against PCV2, Campylobactor coli and Helicobactor cerdo. Therefore, the latter 
two organisms were included in the challenge inocula in order to challenge the three groups i.e., 
controls, PCV2 only and PCV2 plus Campylobactor coli and Helicobactor cerdo vaccinates, 
simultaneously. Typical clinical signs or gross lesions of PMWS were not observed in either 
control or vaccinated pigs. Microscopic lesions reported in subclinical PCV2 infection [125] 
were observed in both controls and PCV2 vaccinates. Further, the two groups were not different 
on IHC scoring. These observations indicate that while the challenge inoculum likely rendered 
its effect inducing microscopic lesions there was no progression to clinical PMWS. The vaccine 
had little or no effect in either inducing a humoral response or preventing histological lesions in 
vaccinates. A similar study evaluating the efficacy of a PCV2 vaccine by using a different 
challenge model i.e., intranasally administered dose of 2 x 10
4.2
 per pig, reported mild lesions 
with no significant differences between vaccinated and control pigs [60]. In the present study,   a 
relatively larger challenge dose and multiple days of challenge were employed; there was an 
initial loading dose of 1.6 x 10
5
 TCID50 per pig followed  by an oral dose of 3.6 x 10
3
 TCID50 of 
PCV2 per pig for next 3 days. Previous PCV2 challenge studies have yielded variable results 
with regard to the production of disease [42, 45, 46, 258].  In the present study it may be that 
previous exposure/priming, or a protective concentration of MDAs precluded the development of 
clinical infection.  Nevertheless available studies emphasize the frequent difficulties in modeling 
PCV2 infection in randomly selected pigs from the commercial swine operations that would be 
candidates for PCV2 vaccination.   
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 In conclusion, we examined the effects of a prototypical inactivated adjuvanted vaccine 
in inducing active immunity in young piglets against PCV2 with limited success. Further studies 
using varying vaccine antigen doses in combination with different adjuvants administered to 
piglets with defined concentrations of MDAs are required to further address the approach of 
inducing active immunity in young passively immune pigs. 
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CHAPTER 3: IMMUNOGENICITY OF LAMBDA PHAGE PARTICLES DISPLAYING 
  PORCINE CIRCOVIRUS 2 (PCV2) CAPSID PROTEIN     
  IMMUNODOMINANT REGIONS   
1. Introduction 
Porcine Circovirus 2 (PCV2) are small, non-enveloped, single stranded DNA viruses 
with a circular genome protected by the capsid [22]. One of the diseases caused by the virus, 
post-weaning multisystemic wasting syndrome (PMWS), sparked severe outbreaks in recent 
years in Canada causing considerable economic losses to the swine industry [245]. It affects, 
typically, young pigs between 8-16 weeks of age that are in early grower and late nursery stages 
with high fatality rates [114]. Virtually all the commercial pig farms are infected [114]. PCV2 
viruses are hardy, persisting in the farm environment for long periods of time [75]. Therefore, is 
considered to be the only effective method of controlling disease outbreaks. At present, there are 
four commercial PCV2 vaccines available in Canada [96]. All are inactivated vaccines and 
contain either whole PCV2, PCV1 engineered to express PCV2-Cap replacing its own capsid, or 
PCV2-Cap expressed from a Baculovirus vector [174, 259] and may contain varying amounts of 
immune irrelevant proteins. Vaccines containing large amounts of unwanted proteins can lead to 
adverse injection site reactions [260, 261]. Propagation of PCV2 for vaccine production is time 
consuming, expensive and laborious process [65]. Further, the inactivation process of PCV2 
vaccine antigens may involve corrosive and known carcinogenic chemicals such as beta-
propiolactone and  may alter the protective immune epitopes, thereby compromising an effective 
immune response [260]. Hence, there is a need for attempting novel strategies to develop 
economical, feasible and effective PCV2 vaccines.  
Inexpensive vaccines have been developed using filamentous [228, 229, 239, 262] and 
lytic T4 [230, 231] bacteriophage display systems. They were shown to be immunogenic and 
potent when administered to laboratory animals. Major coat protein (pVlll) and minor coat 
protein (plll) were used as fusion partners in developing filamentous phage display vaccines. The 
T4 display system fuses peptides to the small outer capsid protein (SOC) or the highly 
immunogenic outer capsid protein (HOC), or both. Lambda phage was suggested as a display 
vehicle for developing vaccines [235]. The lambda display technique has been used to fuse a 
wide variety of foreign peptides to bacteriophage surface molecules mainly to target high affinity 
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tissue ligands [188, 197, 234, 237]. Peptides can be fused to either lambda major tail protein (V) 
[236], or the head protein D [232]. The latter exists as about 140 trimers bound to the underlying 
major head protein E.  Protein D is considered an ideal fusion partner, because of its surface 
location and high number of copies available for fusing foreign peptides [188].   
In general, phage vaccines offer many attractive features compared to other types of 
vaccines. They do not replicate in eukaryotic cells and are shown to be safe by the oral route in 
human volunteers [187].  Large-scale production is inexpensive, simple and extremely rapid 
[210]. Being particulate antigens, phage is taken up by antigen-presenting
 
cells (APCs) [213] and 
processed through both MHC I and II pathways [215] ensuring enhanced and balanced immune 
response. Phage lambda contains many thousands of CpG motifs per genome that would 
preferably contribute for induction of CMI [263].  Additionally, phage vaccines don’t require an 
adjuvant, can be administered orally or nasally, and are stable under normal storage conditions 
and a wide pH range (3-11) [216]. The latter characteristics are ideal for a veterinary vaccine.  In 
this study, we test the immunogenicity of lytic bacteriophage lambda displaying four 
immunodominant regions of PCV2-Cap in an attempt to develop a potential PCV2 vaccine 
candidate using a novel approach. 
2. Materials and methods           
2.1.Designing a gene fusion expressing immunogenic regions of PCV2-Cap protein  
A particle preparation process incorporating safety and security features was developed 
for making LDP (lambda display particle), LDNAP (lambda DNA particle) and L2DP (lambda 
display-DNA particle) with utility as surface display agents and vaccines [31]. Several regions of 
the PCV2-Cap were previously found to discriminate between common PCV1 and type-specific 
PCV2 antigens and to represent immunorelevant epitopes for virus type discrimination [32].  We 
prepared a LDP displaying four regions of the ORF2 capsid (CAP) gene from PCV2.  The amino 
acid sequences for the capsid proteins of ten PCV2 isolates were compared and a consensus 
sequence was chosen for the isolate with the most common amino acid sequence (GeneBank # 
DQ629119).  The nucleotide sequence corresponding to four regions of this isolate, amino acids 
65-87, 113-146, 158-183 and 194-207, were codon optimized for expression in E. coli (changing 
66 of 97 codons as compared to sequence AF055392), joined by 3 amino acid spacers, and fused 
to the COOH-end of codon optimized (55 of 110 codons) lambda D gene via a 5 amino acid 
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linker. The D-CAP gene fusion was made synthetically, confirmed by sequence analysis, and 
used to make several plasmids (termed pD-CAP), in which the D-CAP gene fusion was either 
constitutively expressed, or regulated by a temperature sensitive repressor.   
2.2. Determining if pigs contain pre-existing anti-lambda antibodies  
2.2.1. Raising anti-lambda antisera in pigs  
A double CsCl banded unmodified lambda phage was dialysed for 3 hrs each in 1000X 
volumes of phage dialysis buffer (PDB, 0.3 M NaCl, 0.01 M Tris and 0.05 M MgCl2, pH 7.8) 
and then phosphate buffered saline (PBS, 0.0036 M KCl, 0.0014 M KH2PO4, 0.136 M NaCl, 
0.004 M Na2 hrPO4,  pH 7.4). Three piglets 5-6 weeks of age were purchased from a commercial 
farm, identified individually and maintained at the animal care facility at the Western College of 
Veterinary Medicine (WCVM). Doses of either 3×10
8
, 3×10
9
 or 3×10
10
 phage particles per Kg 
body weight (b.wt.) in 0.5 ml volume were administered three times intradermally to the piglets 
at three week intervals using an injector gun (Biojector 2000, Bioject Inc. USA). Sera were 
collected prior to each inoculation and two weeks after the last inoculation. The injection site 
reactions, rectal temperatures (twice per day for 3 days) following each inoculation, and the 
general health of the pigs were monitored throughout the experiment. The objective of the use of 
the three doses employed in this experiment was to gather dose response data to establish the 
dose for the phage display vaccine. 
2.2.2. Gnotobiotic and farm pig sera (field sera) 
Sera from eight gnotobiotic pigs provided by Dr. Steve Krakowoka, the Ohio State 
University, Columbus, Ohio, were used as negative control sera. Sera from fifty-five individual 
pigs from five farms near Saskatoon, Canada were used as test samples.  
2.2.3. Indirect ELISA (iELISA) measuring anti-lambda antibodies 
A double CsCl banded lambda phage preparation was dialysed for 3 hr each in 1000X 
volume of PDB followed by ELISA coating buffer (Na carbonate 0.05M, pH 9.2). Alternative 
columns (1, 3, 5 etc.) of ELISA plates were coated with 8×10
9
 phage particles per 100 µL per 
well in coating buffer. The remaining columns (2, 4, 6, etc.) were dispensed with 100 µL per 
well coating buffer. Plates were incubated overnight at 4
o
C. Coating buffer was then removed 
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and plates were washed (5X) with PBS + 0.05% Tween20 (PBST). Blocking buffer, PBST + 5% 
skimmed milk was added in 200 µL volumes per well and plates were incubated for 30 min at 
37
o
C. Serum samples diluted at 1:100 in blocking buffer were added in 100 µL quantities into 
antigen coated and non-coated wells in duplicate (four wells per sample), plates were maintained 
overnight at 4
o
C and then washed (5X) with PBST. Each well was dispensed with 100µL per 
well of 1:5000 diluted HRP-conjugated protein A (Invitrogen, Carisbad, CA, USA) in blocking 
buffer and plates were incubated 1 hr at 37
o
C. After a similar washing step, 100µL per well of 
2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS) peroxidase 
substrate (KPL inc, Gaithersburg, Maryland, USA) was added and incubated for 10-20 min at 
ambient temperature until color developed. The reaction was stopped by adding 50µL of 5% 
SDS per well. The optical density of the solution in the wells was read at 405 nm. The OD value 
for each sample was corrected by subtracting the average OD value for two non-antigen coated 
wells from the corresponding value for two antigen coated wells.  
2.3. Demonstrating expression of D-CAP in transformed E. coli cells  
2.3.1. Protein extraction  
E. coli strain R594 F lac-3350 galK 2 galT22 rpsL 179 IN (rrnD-rrnE) l [264] was 
transformed with pD-CAP. Culture of transformed and untransformed cells were grown 
overnight at 30
o
C, diluted 1:20 in fresh media, then grown at 30
o
C
 
to an OD575 = 0.45 and cells 
were harvested by centrifugation (Beckman, J2-21) at 6000 rpm for 10 min. The cell pellets were 
resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl and 10mM Imidazole) containing 
proteinase inhibitor cocktail (Roche Diagnostics Canada, Laval, Quebec), sonicated (six, 10 s, 
pulsed bursts, 50% duty cycle) and the cellular debris was removed by centrifugation at 15,000 g 
for 10 min. Samples were immediately frozen in liquid nitrogen and stored at -70
o
C. Protein 
concentrations were estimated by Bradford method [252].  
2.3.2. Dot blot assay  
Diluted protein extracts from transformed, and untransformed E. coli cells, partially 
purified PCV2 antigen from pig kidney (PK-15) cell line infected with PCV2, and a lambda 
phage preparation in 1 ml quantities were applied and permitted to pass through a Dot-blot 
apparatus (Bethesda Research Laboratories Inc., Bethesda, MD, USA) with a nitrocellulose 
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membrane (Schleicher & Schuell BioScience Inc., New Hampshire, USA) pre-soaked in tris-
buffered saline (TBS, 20 mM Tris, pH 7.5, 0.5M NaCl). The membrane was removed and 
blocked in TBS + 0.1% Tween20 + 5% Skim milk overnight at ambient temperature. All protein 
extracts, antibodies and the reagents were diluted in TBS containing 0.04% Tween20 (TBST). 
The membrane was washed (3X) with TBST prior to and between each step of the staining 
procedure. The washed membrane was incubated for 1 hr at ambient temperature with anti-PCV2 
polyclonal antiserum from a gnotobiotic pig diluted at 1:200 followed by biotinylated goat anti-
swine serum (Vector Laboratories Inc., Burlingame, CA, USA) diluted at 1:750 and then 
incubated with streptavidin-alkaline phosphatase (Bio-Rad Laboratories, Hercules, CA, USA) 
diluted at 1:1500. The membrane was washed (3X) in double distilled water (DW) for 5 min, 10 
ml of freshly prepared BCIP/NBT reagent (Invitrogen, Carisbad, CA, USA) was applied as per 
the manufacturer recommendations, and the membrane was incubated until color developed. The 
membrane was washed with DW to stop the reaction.  
2.3.3. iELISA  
   Protein extracts from transformed and untransformed E. coli cells were serially diluted in 
coating buffer. The starting dilution (1:5) was adjusted to contain 21.5 µg total protein per 100µl 
volume. Duplicate wells of an ELISA plate were coated with 100µL of each dilution from the 
respective protein extracts and incubated overnight at 4
o
C. Coating buffer was then removed and 
plates were washed (5X) with PBST. Blocking buffer was added at 200 µL per well and plates 
were incubated for 30 min at 37
o
C. Blocking buffer was removed and the plate was washed (5X) 
with PBST.  Anti-PCV2 polyclonal antiserum from a gnotobiotic pig was dispensed at a dilution 
of 1:100 in PBST, 100 µl per well, and incubated at 37
o
C for 1 hr. After washing (5X) in PBST, 
biotinylated protein A (Invitrogen, Carisbad, CA, USA) was added in volumes of 100 µl per well 
at a dilution of 1:5000 in PBST and the plate was incubated at 37
o
C for 1 hr. The plate was 
washed (5X) in PBST and 100 µl per well streptavidin-peroxidase conjugate (ABC reagent, 
Vector Laboratories Inc., Burlingame, CA, USA) diluted in PBST according to the 
manufacturer’s recommendation was added and the plate was incubated at 37oC for 30 min. 3.3’, 
5.5’-tetramethylbenzidine (TMB) substrate (KPL Inc., Gaithersburg, Maryland, USA) was added 
100 µl per well, after washing the plate (5X) with PBST. The reaction was stopped by adding 50 
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µl per well of 1M H2SO4 after 15 min of incubation at ambient temperature. The optical density 
of the solution in the wells of the plate was read at 450 nm. 
2.4. Preparation of LDP D-CAP vaccine 
LB medium (0.5% w/v NaCl, 0.5% w/v Bacto yeast extract, 1% w/v Bacto tryptone), 
containing 0.01M MgCl2 and 0.01M Tris, pH 7.6, was inoculated with an overnight culture of 
594 [pD-CAP] and incubated at 39
o
C. At OD575=0.1, the culture was infected at a multiplicity of 
infection of 0.1 with λimm434cI. Incubation was stopped at ~3 hpi which was accompanied by 
sharp drop of OD575 and visually observable cell debris. The lysate was then clarified by 
centrifugation at 10,000 rpm for 10 min in JLA 16.25 rotor in Avanti J-E centrifuge (Beckman 
Coulter, Inc., Fullerton, CA, USA) and held overnight at 4
o
C. Viable phage titers of the lysates 
(2 L volumes in 4 L flasks) were vary in the range of high 10
9
 per ml. NaCl and polyethylene 
glycol (PEG) MW 1600-1750 were added up to 0.5 M and 4% (w/v), respectively, and the lysate 
was held overnight at 4
o
C. Phage was pelleted by centrifugation at 8,000 rpm (as above) for 30 
min and the pellets were resuspended in buffer (TM, 0.01 M Tris, 0.01 M MgSO4 .7H2O and 0.1 
M NaCl, and pH 7.5). The phage suspension was further concentrated by a second PEG pelleting 
and banded in a 1.5g per ml CsCl gradient run at 45K in SW 60 Ti rotor in L8-M ultracentrifuge 
(Beckman Coulter, Inc., Fullerton, CA, USA). The phage band was recovered and rebanded.  
2.5.  iELISA for phage displaying recombinant D-CAP protein 
The double CsCl banded phage display vaccine plus an unmodified lambda phage 
preparation were dialysed for 3 hrs each in 1000X volume of phage dialysis buffer and then 
ELISA coating buffer. The preparations were serially diluted in coating buffer and the starting 
dilution was adjusted to contain 3×10
10
 phage particles per 100µL. Duplicate wells of an ELISA 
plate were coated with 100µL of each dilution from the respective phage preparation and 
incubated overnight at 4
o
C, and the ELISA protocol described (2.3.3) was used to detect D-CAP. 
2.6.   Evaluation of porcine Circovirus 2 phage display vaccine  
2.6.1. Immunization trial 1 
The LDP-D-CAP vaccine and unmodified lambda phage preparations were dialysed for 3 
hrs each in 1000X volume of PDB followed by PBS, pH 7.4. Three piglets at 7 week of age were 
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purchased from a farm where PCV2 vaccination was not practiced, identified individually and 
maintained at the animal care facility at the WCVM. Two piglets were immunized each with 
1×10
10
 vaccine phage particles per Kg b.wt. intradermally three times at 2-week intervals using 
an injector gun. Total volume was adjusted to 0.5 ml. The remaining pig (control) was injected 
with the unmodified lambda phage preparation at the same dose regime. Sera were collected 
prior to each inoculation and 2 weeks after the last immunization. Body weight, general health 
and the injection site reaction (if any) were monitored throughout the experiment. 
2.6.2. Immunization trial 2 
The second immunization trial was carried out with twelve piglets at 7 week of age 
purchased from a farm where PCV2 vaccination is not practiced. Piglets were randomized into 
vaccinate and control groups based on maternally-derived PCV2 antibody levels to ensure both 
groups were contained piglets with a similar levels of these antibodies. A similar procedure and 
dose regimen to trial 1 were used.        
2.6.3. Skin testing for delayed type hypersensitivity (DTH) reaction      
On the day following the last serum collection in the second immunization trial, both 
control and vaccinated pigs were injected intradermally on the left ear at two different sites with 
250 µg of unmodified lambda phage and partially purified PCV2 antigen from infected PK-15 
cells in 0.1 ml PBS using a 28-gauge needle. They were injected similarly on the right ear with 
0.1 ml of PBS and 250 µg of uninfected PK-15 cell lysate in 0.1 ml PBS to serve as placebo for 
the respective antigens. One control and one vaccinated pig received 250 µg of 
Phytohemagglutinin-P (PHA-P, Sigma-Aldrich Canada Ltd. Oakville, Ontario) in 0.1 ml PBS on 
the right ear as a positive control. Skin biopsies were collected using 8-mm biopsy punch (Acu-
punch, Acuderm inc., USA) 48 hr post-injection, fixed in 10% formol saline, embedded in 
paraffin, sectioned at 5μm and stained with haematoxylin-eosin (H & E). The stained tissues 
were evaluated without knowledge of the identity of the sample on a scale of 0 to 3+ by a 
pathologist. The scale is 0=negative, 1+=minimal, 2+=moderate, and 3+=Extensive.    
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2.6.4. iELISA measuring anti-lambda and anti-PCV2 antibodies 
Anti-lambda antibodies were measured by iELISA as previously described in 2.2.3. Anti-
PCV2 antibodies were detected by iELISA as previously described [107]. Briefly, ELISA plates 
were coated with partially purified PCV2 antigen from PCV2 infected PK-15 cell lysate and 
uninfected PK-15 cell lysate in alternative columns of wells as positive and negative antigens, 
respectively, and their optimum concentrations were determined by checkerboard titration. Plates 
were incubated overnight at 4
o
C. Coating buffer was then removed and plates were washed (5X) 
with PBST. Blocking buffer, PBST + 0.2% gelatin (Sigma-Aldrich Inc., St. Louis, MO, USA) 
was added 200 µL per well and plates were incubated for 30 min at 37
o
C. Serum samples diluted 
at 1:100 in PBST were added into wells coated either with positive or negative control antigen, 
100 µL per well in duplicates (four wells per sample). Plates were incubated at 37
o
C for 1 hr and 
then washed (5X) with PBST.  The remaining steps of the ELISA protocol are as described in 
2.2.3. 
2.6.5. Virus neutralization assay (VNA) 
 PCV2-specific neutralising antibodies in three pigs i.e., one control and two vaccinated 
pigs prior to and after the last immunization were measured by VNA as previously described [78, 
265].  Briefly, each serum sample was heat inactivated at 56
0
C for 30 min and serially diluted 
twofold up to 1:1024 in minimum essential medium (MEM). An equal volume of PCV2 adjusted 
to contain 300 TCID50 per 0.1 ml was added to serum samples and incubated 2 h at 37
0
C. The 
mixtures were added to a flat-bottomed 96-well microtiter plate that was seeded with 1.5 X 10
5
 
PK-15 cells per well and incubated at 37
0
C for 6 hr in a 5% CO2 atmosphere. The plate was then 
incubated for 48 hr under similar conditions and the resulting monolayers were treated with 300 
mM D-glucosamine (Sigma-Aldrich Inc., St. Louis, MO, USA) 25μl per well for 10 min. Cells 
were washed twice with 100μl of MEM per well and replenished with 200μl of MEM per well 
and incubated as before for an additional 16 hr. The monolayers were washed once with PBST, 
allowed to air dry for 1 hr and fixed in 80% cold acetone for 10 min. The air dried cells were 
stained for PCV2 antigens using immunoperoxidase assay [83]. The neutralization titers were 
expressed as the reciprocal of the highest serum dilution that completely blocked the infection in 
PK-15 cells, as compared to virus control. 
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2.6.6. Immunoblots  
The D-CAP phage display vaccine and the unmodified lambda phage preparations were 
dialysed for 3 hrs in 1000X volume of phage dialysis buffer. The phage preparations and a PCV2 
infected cell lysate were adjusted to contain equal amount of total protein and boiled in SDS-
PAGE sample buffer (0.0625M Tris pH 6.8, 4.65% (w/v) SDS, 20% (v/v) glycerol, 10% (v/v) β-
mercaptoethanol, 0.025% (w/v) bromophenol blue) for 5 min and separated by 12% 
polyacrylamide gel in Mini-PROTEAN 3 electrophoresis cell (Bio-Rad Laboratories, Hercules, 
CA, USA) along with protein markers (Bio-Rad Laboratories, Hercules, CA, USA). Proteins 
were transferred to nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA, USA) at 400 
mA for 90 min. The membranes were blocked overnight in Tris-buffered saline (TBS, 20 mM 
Tris, pH 7.5, 0.5M NaCl) containing 0.1%  Tween20 and 5% skimmed milk. The blots were 
washed twice in TBST for 5min followed by reacting either with anti-PCV2 polyclonal from a 
gnotobiotic pig or with serum taken from a pig prior to and after vaccination, at a dilution of 
1:200 in TBST at ambient temperature for 1 hr. After washing the membranes 3X (for 5, 15, and 
5 min) with TBST, they were incubated with biotinylated protein A (Invitrogen, Carisbad, CA, 
USA) at a dilution of 1:1500 in TBST for 1 hr at ambient temperature. The membranes were 
rinsed 3X (as above) with TBST and incubated with streptavidin-alkaline phosphatase (Bio-Rad 
Laboratories, Hercules, CA, USA) at a dilution of 1:1500 in TBST for 1.5 h at ambient 
temperature. The blots were washed 3X in DW for 15 min and the reaction was visualized by 
applying freshly prepared BCIP/NBT reagent (Invitrogen, Carisbad, CA, USA) as per the 
manufacturer recommendation. The color development was stopped by rinsing the membranes 
with DW. 
3. Results 
3.1. Raising anti-lambda hyperimmune sera in pigs 
 There was a gradual increase in anti-lambda antibody levels following the second and 
third immunization among three pigs that received 10-fold varying doses of lambda phage 
antigen (Fig. 3.1 & 3.2) during the experiment undertaken to raise anti-lambda hyperimmune 
sera. A dose dependent response was evident at the second immunization. However, the third 
immunization eliminated the dose dependency.  
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3.2. Determining if pigs contain pre-existing anti-lambda antibodies 
There was no significant difference (p > 0.05) between mean anti-lambda antibody levels 
for 55 individual pig serum samples (field sera) from five different farms and eight gnotobiotic 
pig sera that were employed as presumptive negative anti-lambda antisera control (Fig 3.3). Field 
and negative control sera (Fig. 3.3) were significantly different (p < 0.05) from the hyperimmune 
serum sample (positive control); sera from the pig received 3 × 10
10
 lambda particles per Kg 
b.wt. following third immunization, see Fig. 3.2).  
3.3. Assessing for the expression of D-CAP fusion protein in 594 [pD-CAP] cell extracts 
The dot blot assay (Fig 3.4) showed a greater reaction with the 594 [pD-CAP] extract (b) 
compared to a slight background reaction with E. coli 594 extract (a). As expected, PCV2 
antigen reacted most intensely with anti-PCV2 polyclonal antiserum from a gnotobiotic pig (c). 
In contrast, there was no reactivity of lambda phage with the anti-PCV2 polyclonal antiserum 
(d). Similarly, ELISA (Fig 3.5) showed higher ODs throughout a series of dilutions from 594 
[pD-CAP] extract compared to that of E. coli 594 extract, most intensely at 1:5 dilution.  
3.4. Demonstrating D-CAP displayed in LDP vaccine  
The ELISA data showed significantly higher reactivity throughout a series of phage 
display vaccine dilutions with anti-PCV2 polyclonal antiserum from a gnotobiotic pig compared 
to corresponding dilutions containing an equal number of unmodified phage lambda particles 
(Fig. 3.6) indicating the presence of recombinant PCV2-CAP protein in the phage display 
vaccine particles. 
3.5. Anti-lambda and anti-PCV2 antibody response following phage display vaccination  
Evaluation of immune responses to lambda phage coat proteins in pigs receiving either 
LDP-D-CAP or unmodified phage preparations revealed a very low level of anti-lambda 
antibodies prior to the experiments that increased gradually following each immunization (Fig. 
3.7 & 3.9). This finding is in agreement with our previous observation that pigs contain very 
low-to undetectable anti-lambda antibodies (Fig. 3.3).  
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Three piglets in the first vaccine trial had low levels of anti-PCV2 antibodies (Fig. 3.8). 
One vaccinate responded at primary (open bar) and the other responded at the second (closed 
bar) vaccination. Third immunizations resulted in no increase in the response in one of the 
vaccinates (open bar) while the other had a diminished anti-PCV2 antibody level (closed bar). 
The control pig had low and stable levels of PCV2 antibodies throughout the experiment 
(hatched bar).  
 Grouping pigs based on the level of anti-PCV2 antibodies prior to vaccination in the 
second trial ensured that both control and immunized pigs had a similar level of maternally-
derived anti-PCV2 antibodies (MDPCV2A) at the beginning of the experiment (Fig. 3.10). The 
vaccinates had significantly (p < 0.05) higher anti-PCV2 immune responses following primary 
vaccination, which plateaued following the second vaccination and slightly decreased after the 
third vaccination. The level of anti-PCV2 antibodies among controls remained low and constant 
throughout the experiment. Two of the LDP-D-CAP immunized pigs tested had considerably 
higher PCV2 neutralizing antibody titers compared to a pig that received lambda control 
inoculum (Table 3.1). 
3.6. Monitoring body weight, general health and injection site reactions 
Both groups increased their body weight by ~17 Kg in 2 week period. There was no 
injection site reaction to lambda control or display vaccine preparation.  
3.7. Immunoblots 
The blots reacted with anti-PCV2 polyclonal antiserum from a gnotobiotic pig (Fig. 
3.11a) or with antiserum from a pig vaccinated with D-CAP phage particles (Fig. 3.11c) 
revealing the D-CAP (arrow) and the 233 amino acid PCV2-Cap (triangle) bands. The blot 
reacted with serum collected prior to vaccination (Fig. 3.11b) shows a lightly stained D-CAP 
(arrow) without detection of a PCV2-Cap band.   
3.8. DTH reaction  
The representative DTH reaction scores are shown in Fig. 3.12.  All pigs vaccinated with 
LDP-D-CAP (3 of 3) were hypersensitive in the DTH assay (Table 3.2) to both lambda phage 
and PCV2 antigens compared to their respective placebo. One of the LDP-D-CAP vaccinated 
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pigs recorded an intensive reaction (3+) to PCV2 antigen. Within the control group, 3 of 5 pigs 
were sensitive to lambda while 2 of 4 showed reactivity to PCV2 antigen.  
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Fig. 3.1 The anti-lambda immune response measured by ELISA in three pigs  
  each of which received 3×10
8
, 3×10
9
 or 3×10
10 
phage particles per Kg 
   b.wt. (3X), at 2-week intervals in comparison to the background OD 
   (open bars). Values are the mean + standard error (SE). 
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Fig. 3.2 The anti-lambda antibody response measured by ELISA in individual pigs 
receiving 3×10
8
 (hatched bar), 3×10
9
 (open bar) or 3×10
10 
(closed bar) phage 
particles per Kg b.wt. (3X), at 2-week intervals. 
 
 
 
 
 
 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
Pre-vaccination Primary Secondary Tertiary 
O
D
 4
0
5
 n
m
Stage of immunization
58 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3 Pre-existing anti-lambda antibody levels in sera from eight gnotobiotic pigs 
(negative control) and sera from 55 conventional pigs from five different farms 
(field sera) were measured by ELISA and compared to an anti-lambda 
hyperimmune serum (positive control). Values are the mean + standard error (SE) 
for gnotobiotic and field sera.  
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Fig. 3.4 Dot-blot assay detecting D-CAP fusion protein in E. coli cell extract using  
 anti-PCV2 polyclonal antiserum from a gnotobiotic pig; a) E. coli R594  
  cell extract, b) E. coli 594 [pD-CAP], c) PCV2 antigen-positive control and d) 
 lambda phage antigen-negative control. The total protein applied per blot site was: 
  a) 165 µg b) 165 c) 5 µg of partially purified PCV2 antigen from PK15 infected 
  cells and d) 1×10
8 
unmodified phage particles. 
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Fig. 3.5 Results of ELISA measuring D-CAP fusion protein in an E. coli cell extract 
 using anti-PCV2 polyclonal antiserum from a gnotobiotic pig. Serial dilutions 
  were made of a protein extract obtained from R594 [pD-CAP] E. coli cells (■). 
 Corresponding dilutions were made of a protein extract obtained from R594 
 E. coli cells (▲). The total protein coated per well at 1:5th dilution was 21.5 µg. 
 
 
 
 
 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
1:5th 1:10th 1:20th 1:40th 1:80th
O
D
 4
5
0
 n
m
Dilution 
61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3. 6 Results of ELISA measuring phage displayed D-CAP fusion protein using anti-
PCV2 polyclonal antiserum from a gnotobiotic pig. Serial dilutions of LDP-D-
CAP vaccine (■) were made. Corresponding dilutions were made of an equivalent 
number of unmodified lambda phage particles (▲). The number of phage 
particles in the undiluted preparation was 3×10
10 
per well. 
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Fig. 3.7 Results of ELISA measuring anti-lambda antibody response in two vaccinated  
  pigs (closed & open bars) receiving 1 × 10
10
 LDP-D-CAP per Kg b.wt.  
   intradermally without incorporating an adjuvant, 3X at 2-week intervals, and a 
   control pig (hatched bars) receiving similar doses of unmodified lambda  
   particles. 
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Fig. 3.8 Results of ELISA measuring anti-PCV2 antibody responses in two vaccinated  
  pigs (closed & open bars) receiving 1 × 10
10
 LDP-D-CAP per Kg b.wt.   
  intradermally without incorporating an adjuvant, 3X at 2-week intervals, and a  
  control pig (hatched bars) receiving similar doses of unmodified lambda particles.  
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Fig. 3.9 Results of ELISA measuring anti-lambda immune antibody responses in six  
  vaccinated pigs receiving 1 × 10
10
 LDP-D-CAP per Kg b.wt. intradermally  
  without incorporating an adjuvant, 3X at 2-week intervals (closed bars), and six  
  controls (open bars) receiving similar doses of unmodified lambda particles.  
  Values are the mean + standard error (SE). 
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Fig. 3.10 Results of ELISA measuring anti-PCV2 antibody responses in six vaccinated 
  pigs receiving 1 × 10
10
 LDP-D-CAP per Kg b.wt. intradermally without 
 incorporating an adjuvant, 3X at 2-week intervals (closed bars), and six controls 
 (open bars) receiving similar doses of unmodified lambda particles. Values are the 
 mean + standard error (SE). 
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Fig. 3.11 Western blots demonstrating phage displayed D-CAP fusion protein using: (a)  
  anti-PCV2 polyclonal antiserum from a gnotobiotic pig; (b serum from a pig prior 
   to vaccination; and (c) serum from a pig after vaccination. Lanes; 1) Protein mass 
   marker, 2) partially purified PCV2 antigen from PK-15 infected cells, 3) LDP-D- 
  CAP from heat-disrupted phage particles, and 4) similarly disrupted unmodified 
   phage particles. Arrow indicates D-CAP protein. Triangle points to PCV2  
  cap protein (positive control). 
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Fig. 3.12. Photographs of representative DTH reaction scores: (a) 0, (b) 1+, (c) 2+  
  and (d) 3+ based scoring of H & E stained skin biopsy tissues. Original  
   magnification (a-d): Magnification ×50. The scale is 0=negative, 1+=minimal, 
   2+=moderate, and 3+=Extensive 
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4. Discussion 
Phage display was examined as a potential vaccination strategy for minimizing the 
economic losses due to PMWS caused by PCV2 infection. There is renewed interest in 
developing new biological agents that can replace traditional vaccines [197], [214, 266]. We 
prepared lambda particles displaying recombinant PCV2-Cap , i.e., LDP-D-CAP. The design of 
LDP-D-CAP vaccine was based on information showing that immunogenicity of PCV2, relative 
to PCV1, was mapped to four dominant immunoreactive areas of the PCV2-Cap [14], which 
were shown to render protection against the disease [259].  
We first demonstrated expression of the recombinant D-CAP protein in E. coli 594 [pD-
CAP] cells by the Dot-blot assay and ELISA. In the Dot-blot assay, PCV2 antigen and the 
lambda phage served as the positive and negative controls, respectively. In both instances, we 
used anti-PCV2 polyclonal antisera from gnotobiotic pigs as the primary antibody.  Gnotobiotic 
pigs are born by caesarean section and kept thereafter in a microbe free environment [38, 39]. 
These pigs were inoculated with PCV2 to raise anti-PCV2 polyclonal antisera and are considered 
devoid of antibodies against any other microbes. This serum was used throughout the 
experiments to detect the expression of recombinant D-CAP in E. coli cells and on LDP.  
Lambda phage possesses an ability to display large D-fusion peptides at high display 
density [235]. The LDP-D-CAP display phage were concentrated by double CsCl gradient to 
purify them from lower buoyant density lipopolysaccharides (LPS) and, from contaminating 
bacterial proteins that are expelled from the CsCl gradient. The reactivity of LDP-D-CAP with 
anti-PCV2 polyclonal from a gnotobiotic pig by ELISA was significantly higher than that of the 
unmodified lambda phage preparation indicating that D-CAP fusion proteins were displayed on 
the LDP-D-CAP vaccine particles. 
The background reaction observed in the Dot-blot assay and ELISA with protein extracts 
from E. coli is because of non-specific binding of polyclonal sera with bacterial proteins. We 
have repeatedly observed a very low intensity reaction between double CsCl purified unmodified 
lambda phage and anti-PCV2 polyclonal sera from gnotobiotic pigs in our immunological 
assays. This finding indicates that the CsCl purified lambda phage preparation is free from 
bacterial contamination. 
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We tested the LDP-D-CAP in pigs, the end-target species  to avoid the swamping effect 
reported by similar vaccine experiments [240] and the common criticism of having to extrapolate 
laboratory animal data to the natural host. The approach provided valuable data to establish a 
dose regimen for intradermal injection in pigs. We addressed an unknown critical issue of 
whether pigs contain pre-existing anti-lambda antibodies. This information was vital to ensure an 
effective immune response by phage vaccines without a risk of being suppressed by the pre-
existing carrier specific immunity. There are conflicting reports indicating that pre-existing 
carrier specific antibodies could enhance [267], have no effect [268, 269] or suppress [270] the 
target vaccine antigen specific immune response.  
For testing sera from conventional pigs for anti-lambda antibodies, we first raised anti-
lambda hyperimmune sera in pigs as the positive control. This trial was designed in such a way 
that we would be able to determine the dose response to phage coat antigens and thereby decide 
the optimum dose of phage display vaccine in the next experiment. Three 10-fold varying doses 
of lambda phage (3×10
8 [≈0.016 μg phage DNA], 3×109, 3×1010 per Kg b.wt.) were employed to 
raise anti-lambda antibodies starting with about 10 Kg piglets. 
We employed the ELISA described by March et.al. [240] measuring anti-lambda 
antibodies in sera collected at different time points during the course of raising hyperimmune 
sera. There was a gradual and significant increase in anti-lambda antibodies following the second 
and third immunizations in individual animals. The dose dependent immune response was 
clearly evident at the second immunization. The third dose eliminated any significant difference 
in immune response between the lowest and the highest dose suggesting that the lowest dose 
should be sufficient for vaccination when unmodified lambda phage is administered three times.  
For addressing the important question of whether pigs have pre-existing anti-lambda 
antibodies, we analysed the ELISA data pertaining to field samples (conventional pig sera) along 
with the presumed negative (gnotobiotic pig sera to PCV2) and the positive control (anti-lambda 
hyperimmune serum). There was no significant difference (p > 0.05) between the negative 
standard and the test sera. However, both groups were significantly different (p < 0. 05) from the 
positive standard. These data indicate pigs contain very low (or no) anti-lambda antibodies. This 
finding assures that phage vaccines can be administered to pigs without the risk of suppression of 
the target vaccine antigen specific immune response by pre-existing carrier immunity.  
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We undertook LDP-D-CAP immunization trial in 7-wk old pigs using an intermediate 
dose of 1×10
10
 vaccine phage particles per Kg b.wt. in 0.5 ml administered three times at 2 week 
intervals via an intradermal route using an injector gun to increase the chance for uptake of 
phage vaccine particles by dendritic cells which possibly enhance an immune response [271]. 
The injector gun ensured the accurate delivery of small quantities of vaccine. Our dose regime 
ensures adequate time and number of immune stimulations to study the pattern of vaccine 
antigen specific immune response (anti-PCV2) against the carrier specific (anti-lambda) 
response. A similar experiment, in a phage DNA vaccine trial employed doses of 5×10
9
 phage 
per mouse and 4×10
10 
phage per rabbit [240].  There was a evoke a significant immune response 
in pigs at 3×10
8
 unmodified lambda, or 1×10
10
 LDP-D-CAP phage per 1 Kg b. wt. pig.  
Assuming weight of a mouse is 30g, we were able to vaccinate using 1/550
th
 or 1/16
th
 lower 
doses of unmodified lambda or LDP-D-CAP phage particles per Kg b.wt., respectively, 
compared to a dose of 5×10
9
 phage per mouse employed by a lambda DNA vaccine experiment 
[240]. The pattern of carrier specific (anti-lambda) immune response in both vaccination trials 
were similar to that seen during the course of raising known anti-lambda antisera; i.e., a gradual 
increase especially following the second and the third immunization. An adjuvant was not 
included in these experiments.  
Pigs had low levels of anti-PCV2 antibody responses prior to both experiments (at 49 
days of age). This observation is in agreement with the finding of a study that monitored anti-
PCV2 antibody levels in a commercial pig farm from birth to market age (5 – 156 days) 
indicating MDPCV2A declined to a very low level between 40-72 days [87]. Since, it is 
impracticable to find farm pigs free of MDPCV2A due to their widely distributed nature [64, 
83], we minimized the effect of MDPCV2A on the efficacy of LDP-D-CAP by using pigs at 7-
wks of age with minimal levels of MDPCV2A. In contrast, PCV2 vaccines developed then far 
have been tested in pigs at 2-4 weeks of age [60, 148, 149]. These animals assumedly have much 
higher levels of MDPCV2A with unknown effects on the vaccine efficacy. In this respect, we 
also ensured that both the control and vaccinated pigs had the similar low level of MDPCV2A at 
the beginning of the experiment thorough randomization based on ELISA readings on sera 
collected prior to immunization.  
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Anti-PCV2 immune responses to LDP-D-CAP were shown in both the pilot experiment 
with three pigs and the second trial with a larger numbers of pigs. The latter experiment, which 
was a better reflection of the immune response to the vaccine candidate, showed significant anti-
PCV2 antibodies after the primary dose. In contrast to anti-lambda response, subsequent dosing 
did not improve anti-PCV2 antibody levels further, in fact, these were somewhat lowered 
following the third immunization in both experiments. Anti-PCV2 antibody levels in the controls 
that received unmodified phage were low and stable throughout the experiment. The decline in 
the anti-PCV2 immune response following the third vaccination leads us to question whether the 
high level of carrier specific immunity at this stage of the experiment contributed to a suppressor 
effect. In contrast, March et.al. [240] reported in their phage DNA vaccine experiment that there 
was no suppression in the development of vaccine antigen specific immune responses even after 
the fourth vaccination. The different observations can be attributed to differences in the nature of 
the two vaccines. We employed a display vaccine where the amount of vaccine antigen would 
degrade over time, while the phage DNA vaccine antigen is expressed through a mammalian 
expression system over a period that could enable it to overcome a suppressive effect by carrier 
specific immunity. None of the other phage display vaccine studies [228, 231, 239, 262] have 
investigated the effect of carrier specific immunity towards the development of vaccine antigen 
specific immune response though they employed a much higher dose (2×10
10 
- 1×10
13
 per 
mouse) of vaccine phage particles per Kg b.wt.  
We performed western blots to confirm the findings of the ELISA, that vaccine phage 
particles display PCV2-Cap epitopes and that they induce anti-PCV2 antibodies in pigs. The blot 
stained with anti-PCV2 polyclonal antiserum from a gnotobiotic pig showed a clear band with 
the vaccine phage. Consistent with our results, lambda coat proteins for the unmodified lambda 
control did not react with this serum. The reaction with serum from a vaccinated pig showed the 
staining for D-CAP on the phage display vaccine (24.6 kDa-calculated for 221 aa) and PCV2-
Cap (28 kDa observed [48]; 25.9 kDa–calculated for 233 aa) on PCV2 infected cell lysate 
indicating induction of anti-PCV2 immunity. This serum reacted with lambda coat proteins both 
on the vaccine and unmodified phage preparation since vaccination induced anti-lambda 
antibodies as well. Serum collected prior to vaccination did not react with the PCV2-CAP from 
the PK-15 cell lysate. However, pre-immune serum stained D-CAP and another phage band 
lightly (possibly a D-CAP trimer) on the phage vaccine. This reactivity with the phage D-CAP 
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protein could result from a low level of anti-PCV2 antibodies existing prior to vaccination. We 
have consistently observed D-CAP band ran at a relatively higher level than the expected MW. 
This finding is in consistent with a earlier observation [272] that lambda proteins migrate 
relatively more slowly in gels with high bisacrylamide/acrylamide ratios (8:300) which we used 
in our experiments.      
We addressed an important question, namely, whether the LDP-D-CAP can induce 
neutralizing antibodies? Both LDP-D-CAP immunized pigs tested had a considerable increase in 
virus neutralizing titer compared to the level prior to immunization and to a control pig that 
received unmodified lambda particles. This confirmed that phage particles displaying D-fusion 
peptides comprising the four immunodominant regions of PCV2-Cap can induce PCV2 specific 
antibodies. The gene encoding the D-CAP fusion peptide included a string of the 
immunodominant regions from the PCV2-Cap, i.e., ~50% of the amino acids, including eight out 
of nine biologically significant sites. Therefore we probably have included the complete 
repertoire of neutralizing antibody generating epitopes.     
We used DTH reactions to evaluate the ability of LDP-D-CAP to induce CMI because of 
its importance in viral infections. DTH is an inflammatory response. It is characterized by 
infiltration of mononuclear cells following the presentation of antigen by Langerhans cells to 
sensitized Th1 cells at the site of antigen deposition [273]. We evaluated the magnitude of the 
reaction for specific antigens and their placebo in comparison to a severe inflammation elicited 
by PHA-P (positive control). Though all LDP-D-CAP vaccinated (6) and unmodified lambda 
vaccinated control pigs (6) were subjected to skin testing, biopsies could only be collected from 
three vaccinated and five controls.  All vaccinated pigs (3 of 3) showed responses to PCV2 
antigen compared to 2 of 4 controls that received unmodified lambda in place of the phage 
display vaccine. One LDP-D-CAP vaccinated pig had an intensive inflammatory response 
comparable to that of the positive control. All LDP-D-CAP vaccinated (3 of 3) and 3 of 5 
unmodified lambda vaccinated control pigs reacted to lambda phage antigens. Importantly, these 
data confirm the development of cell-mediated immunity to recombinant PCV2-Cap fusion 
protein (D-CAP) following phage display vaccination. Cellular immunity is necessary in 
combating PCV2 replication in affected pigs [134]. The reason that some control pigs reacted to 
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PCV2 antigens is probably due to the presence of sensitized Th1 cells formed prior to our 
vaccination trial.  
Apart from the knowledge that phage particles are safe in eukaryotes [187, 210], substantial 
evidence was generated in the immunization trial to indicate that LDP-D-CAP was safe. First, 
LDP-D-CAP production procedure did not involve any inactivation procedure and the final 
testing preparation contained only the purified non-viable lambda antigens. In contrast, all 
commercial PCV2 vaccines presently available in the North America are subjected to an 
inactivation procedures and probably contained unpurified PCV2 antigens [96, 274]. Secondly, 
we did not observe any untoward injection site reactions even with a dose of 1×10
10 
phage 
particles per Kg b.wt. Thirdly, we have observed a steady increase in body weights of 
immunized pigs, ~ 17 Kg per two weeks indicating good general health without probable 
systemic reactions. Given the fact that production of commercial PCV2 vaccines require either 
propagation of slow growing PCV2 in tissue culture yielding a low viral titer (~10
5
 TCID50 per 
ml) [61, 65, 66] or expression and purification of PCV2 recombinant capsid protein [19, 275], 
we believe that production of lambda vaccines is highly economical because of feasibility to 
produce E. coli lysates containing high titer lambda display particles (~10
9
 per ml, Tables 4.1 & 
4.2). However, a meaningful comparison of the costs for the production of commercially 
available PCV2 vaccines to the lambda display vaccine is not possible at this stage because of 
several reasons. First, we have produced the display vaccine in small quantities only for our 
experiments and secondly, its dosage is not yet fully optimized.  Finally, the price of 
commercially available PCV2 vaccines is not available in the public domain.  
In conclusion, we have developed a potential PCV2 vaccine candidate without 
incorporating any adjuvant in the final preparation, and one that can be very economical.  
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CHAPTER 4: PREPARATION OF LAMBDA DISPLAYING FUSION POLYPEPTIDES 
1. Introduction 
 Lambda phage display technology is considered a better method compared to other 
bacteriophage display systems because of its ability to yield higher display density i.e., higher 
percentage of lambda display fusion partner copies were linked with display peptides [188, 197, 
232-237]. It has multiple uses, notably including gene therapy [276], developing diagnostic 
reagents [241, 242] and  vaccines [277]. There are two basic methods of displaying foreign 
peptides on phage particles: inserting the target gene into the phage genome, or their expression 
through plasmids carrying genetic codes for the fusion peptides of interest [189, 214]. The latter 
method is preferred as it yields mosaic phage particles i.e., particles bearing both wild type and 
those fused to display peptides and, therefore, causing less impact on phage morphogenesis 
[278]. Also, it would not raise the common concern of using genetically modified organisms in 
biological systems. Further, lysogen containing lambda mutant prophage with heat- labile 
repressor protein provides technology for more regulated expression of fusion proteins by 
thermal induction [279, 280]. Heat inactivation of the repressor protein derepresses the lambda 
promoter inducing protein synthesis. We investigated if lambda displaying fusion peptides linked 
to D protein i.e., D-CAP, D-FLAG and D-GFP could be produced using this method.  CAP, 
FLAG and GFP denote four immunodominant regions of PCV2-Cap (chapter 3, section 2.1), 
FLAG tag peptide [281] and Green fluorescent protein, respectively.  
2. Materials and methods 
2.1. Demonstration of thermo regulated expression from lambda promoter  
2.1.1. Thermal induction of cell killing 
 E. coli 594 cells, lysogen containing mutant lambda prophage with heat-labile repressor 
protein, were transformed with pD-FLAG (594 [pD-FLAG]) and the viability of these cells was 
estimated by plating dilution of overnight culture on Tryptone broth agar (TBA, 0.5% w/v NaCl, 
1% w/v Bacto tryptone and 1.1% w/v Bacto agar) at 30
o
C, 37
o
C, 39
o
C and 42
o
C. Percentage of 
viability at each temperature was calculated in relation to viable cell counts (cfu/ml) at 30
o
C.  
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2.1.2. Thermal induction of susceptibility to lambda infection  
 594 [pD-FLAG] cells were cross streaked on λvir and λc172 and incubated at 30oC and 
42
o
C to demonstrate inactivation of repressor at 42
 o
C and, therefore, that cells become 
susceptible to λc172 infection.  
2.2. Protein extraction 
  E. coli 594 strain with lambda heat-labile repressor was transformed with pD-
CAP, pD-FLAG and pD-GFP separately. A single colony from each culture of transformed cells 
was grown overnight at 30
o
C in 25 ml of Tryptone broth (0.5% w/v NaCl and 1% w/v Bacto 
tryptone) containing 50 µg/ml of Ampicillin. Nine flasks, each containing 25 ml of LB medium 
(0.5% w/v NaCl, 0.5% w/v Bacto yeast extract, 1% w/v Bacto tryptone) and the respective 
antibiotic were inoculated with each culture at 1:20 dilution and grown at 30
o
C
 
 until OD575 
reached 0.4. Four of the flasks per culture, each designated 20 min, 1 hr, 1.5 hr or 4 hr were 
transferred to two shaking water baths each set at either 39
o
C or 42
o
C to induce protein 
expression and incubated for designated time periods. The flasks were removed after elapsing 
appropriate time periods, followed by protein extraction. One inoculated flask from each culture 
remained at 30
o
C for a further 1.5 hr to serve as the control for thermal induction of D-fusion 
protein expression. A culture of untransformed E. coli grown at either 39
o
C or 42
o
C served as the 
control for plasmids expressing D-fusion proteins. Cells induced for protein expression and non-
induced and untransformed control cultures were harvested by centrifugation (Beckman, J2-21) 
at 6000 rpm for 10 min. Cell pellets were resuspended in 0.5 ml of TES buffer (0.02M Tris PH 
7.6, 0.002M EDTA PH 7.6 and 0.15M NaCl), added with 0.5 ml of a lysing mixture (0.002M 
Tris PH 7.6, 0.04M EDTA PH 7.6, 0.15M NaCl and 0.87M SDS) and boiled for 3 min. Protein 
extracts were cooled to ambient temperature and added with proteinase inhibitor cocktail (Roche 
Diagnostics Canada, Laval, Quebec) as per the manufactures recommendation. Aliquots were 
stored at -70
o
C. Protein concentration was estimated using NanoDrop® ND-1000 
Spectrophotometer  (NanoDrop Technologics, Inc., Wilmington, DE, USA). 
2.3. Demonstration of D-fusion proteins in E. coli cell extracts by Western blots (WB)  
 Cell extracts were adjusted to contain an equal amount of total protein (delivering 40 μg 
per well of polyacrylamide gel) in phosphate buffered saline (PBS, 0.0036 M KCl, 0.0014 M 
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KH2PO4, 0.136 M NaCl, 0.004 M Na2 HPO4,  pH 7.4) and boiled in SDS-PAGE sample buffer 
(0.0625M Tris pH 6.8, 4.65% (w/v) SDS, 20% (v/v) glycerol, 10% (v/v) β-mercaptoethanol, 
0.025% (w/v) bromophenol blue) for 5 min and separated by 12% polyacrylamide gel in Mini-
PROTEAN 3 electrophoresis cell (Bio-Rad Laboratories, Hercules, CA, USA) along with protein 
markers (Bio-Rad Laboratories, Hercules, CA, USA). Proteins were transferred to nitrocellulose 
membranes (Bio-Rad Laboratories, Hercules, CA, USA) at 400 mA for 90 min. The membranes 
were blocked overnight in Tris-buffered saline (TBS, 20 mM Tris, pH 7.5, 0.5M NaCl) 
containing 0.1%  Tween20 and 5% skimmed milk. The blots were washed twice in TBS 
containing 0.04% Tween20 (TBST) for 5 min prior to reaction with specific primary antibody for 
the D-fusion protein. To demonstrate D-CAP, a blot was reacted with anti-PCV2 polyclonal 
antiserum, from a gnotobiotic pig, at a dilution of 1:200 in TBST at ambient temperature for 1 hr. 
After washing the membrane 3X (for 5, 15, and 5 min) with TBST, it was incubated with 
biotinylated protein A (Invitrogen, Carisbad, CA, USA) at a dilution of 1:1500 in TBST for 1 hr 
at ambient temperature. The membrane was rinsed 3X (as above) with TBST. To demonstrate D-
FLAG, the blot was reacted with anti-FLAG biotinylated BioM5 monoclonal antibody (Sigma-
Aldrich Inc., St. Louis, MO, USA) at 2 μg per ml in TBST at ambient temperature for 1 hr 
followed by washing the membrane 3X (for 5, 15, and 5 min) with TBST. Then both D-CAP and 
D-FLAG membranes were incubated with streptavidin-alkaline phosphatase (Bio-Rad 
Laboratories, Hercules, CA, USA) at a dilution of 1:1500 in TBST for 1.5 h at ambient 
temperature. The blots were washed 3X in DW for 15 min and the reaction was visualized by 
applying freshly prepared BCIP/NBT reagent (Invitrogen, Carisbad, CA, USA) as per the 
manufacturer recommendation. The color development was stopped by rinsing the membranes 
with DW. 
2.4. Preparation and purification of lambda particles displaying D-fusion proteins 
 Preparation of lambda particles displaying D-CAP, D-FLAG and D-GFP fusion proteins 
was as previously described [277]. Three 4 litre flasks containing 2 litres of LB medium (0.5% 
w/v NaCl, 0.5% w/v Bacto yeast extract, 1% w/v Bacto tryptone), containing 0.01M MgCl2 and 
0.01M Tris, pH 7.6, plus 50 µg/ml of either Ampicilin or Kenamycin, were inoculated with an 
overnight culture of 594 cells transformed with one of the plasmids; pD-CAP, pD-FLAG or pD-
GFP, and placed in a shaking incubator cabinet at 39
o
C. When the cells reached an absorbance of 
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A575=0.1, each culture was infected with λimm434cI at a multiplicity of infection of 0.1. The 
cultures were removed from the incubator 3 hr after infection. The lysate was clarified by 
centrifugation at 10,000 rpm for 10 min in JLA 16.25 rotor in Avanti J-E centrifuge (Beckman 
Coulter, Inc., Fullerton, CA, USA) and the supernatant solutions were held overnight at 4
o
C.  
NaCl and polyethylene glycol (PEG) MW 6000-7500 were added to 0.5 M and 4% (w/v), 
respectively, into the supernatant solutions, shaken into solution, and held overnight at 4
o
C.  The 
solutions were centrifuged at 8,000 rpm for 30 min and the enriched phage pellets were gently 
resuspended in buffer (TM, 0.01 M Tris, 0.01 M MgSO4 .7H2O and 0.1 M NaCl, and pH 7.5). 
NaCl and PEG were added to 0.5 M and 4% (w/v), respectively, into pooled resuspended phage 
pellet, and after holding the suspension overnight at 4
o
C, it was repelleted at 8,000 rpm for 30 
min. The second phage-enriched pellet was gently resuspended in TM buffer, solid CsCl was 
added to a density of 1.5 g/cc, and the solution was subjected to centrifugation at 45K in an SW 
60 Ti rotor in L8-M ultracentrifuge (Beckman Coulter, Inc., Fullerton, CA, USA) for 48 hr. The 
phage bands were recovered and rebanded.  
2.5. Viable phage counts by plaque assay 
 Ten-fold dilutions of either phage lysate or banded phage display preparations were made 
in ϕ80 buffer (0.01M Tris and 0.1M NaCl, pH 7.8). One tenth of an ml (0.1 ml) of each dilution 
was mixed with 0.25 ml overnight broth culture of E. coli strain 594, R594 F lac-3350 galK 2 
galT22 rpsL 179 IN (rrnD-rrnE) l [264] in a sterile test tube to what was added 3ml of top agar 
(0.5% w/v NaCl, 0.65% w/v Bacto agar, 1% w/v Bacto tryptone) maintained in liquid at 40
o
C. 
The mixtures were immediately poured on Tryptone broth agar and incubated at 37
0
C overnight. 
Clear plaques on plates corresponding to three consecutive dilutions were counted and average 
plaque count (pfu/ml) was calculated accordingly.      
2.6. Total phage counts 
 Total phage counts, i.e., including both live and dead phage, of banded phage display 
preparations were calculated based on A260. One microgram of DNA is calculated to be 
equivalent to 1.2 х 1010 lambda particles (unpublished data).     
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2.7. Demonstration of phage displaying D-CAP by indirect ELISA (iELISA) 
    The middle and bottom bands of lambda displaying D-CAP and an unmodified lambda 
phage preparations were dialysed for 3 hr each in 1000X volume of phage dialysis buffer (PDB, 
0.3 M NaCl, 0.01 M Tris and 0.05 M MgCl2, pH 7.8) and then ELISA coating buffer (Na 
carbonate 0.05M, pH 9.2). The preparations were serially diluted in coating buffer and the 
starting dilution was adjusted to contain 3×10
10
 phage particles per 100µL. Duplicate wells of an 
ELISA plate were coated with 100µL of each dilution from the respective phage preparation and 
incubated overnight at 4
o
C. Coating buffer was then removed and plates were washed (5X) with 
PBST. Blocking buffer was added at 200 µL per well and plates were incubated for 30 min at 
37
o
C. Blocking buffer was removed and the plate was washed (5X) with PBS containing 0.05% 
Tween20 (PBST).  Anti-PCV2 polyclonal from a gnotobiotic pig was dispensed at a dilution of 
1:100 in PBST, 100 µl per well, and incubated at 37
o
C for 1 hr. After washing (5X) in PBST, 
biotinylated protein A (Invitrogen, Carisbad, CA, USA) was added at 100 µl per well at a 
dilution of 1:5000 in PBST, and the plate was incubated at 37
o
C for 1 hr. The plate was washed 
(5X) in PBST and 100 µl per well of streptavidin-peroxidase conjugate (ABC reagent, Vector), 
diluted in PBST according to the manufacturer’s recommendation was added and the plate was 
incubated at 37
oC for 30 min. 3.3’, 5.5’-tetramethylbenzidine (TMB) substrate (KPL Inc., 
Gaithersburg, Maryland, USA) was added at 100 µl per well, after washing the plate (5X) with 
PBST. The reaction was stopped by adding 50 µl per well of 1M H2SO4 after 15 min of 
incubation at ambient temperature. The plate was read at 450 nm. 
2.8. Demonstration of phage displaying D-CAP by Western blot 
  Two dialysed phage preparations, middle band of lambda displaying D-CAP and 
unmodified lambda preparations, and a PCV2 infected cell lysate as the positive control for 
PCV2-Cap were adjusted to contain equal amount of total protein and boiled in SDS-PAGE 
sample buffer for 5 min and separated by 12% polyacrylamide gel in Mini-PROTEAN 3 
electrophoresis cell (Bio-Rad Laboratories, Hercules, CA, USA) along with protein markers 
(Bio-Rad). Proteins were transferred to nitrocellulose membranes (Bio-Rad Laboratories, 
Hercules, CA, USA) at 400 mA for 90 min. Blots were reacted with one of anti-PCV2 polyclonal 
from a gnotobiotic pig, serum from a conventional pig immunized with lambda displaying D-
CAP or anti-lambda polyclonal from a conventional pig, at a dilution of 1:200 in TBST at 
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ambient temperature for 1 hr, to demonstrate D-CAP expression in the display preparation, 
estimate D-CAP:wild type D ratio, and to demonstrate lambda regular proteins respectively. 
After washing the membrane 3X (for 5, 15, and 5 min) with TBST, it was incubated with 
biotinylated protein A (Invitrogen, Carisbad, CA, USA) at a dilution of 1:1500 in TBST for 1 hr 
at ambient temperature. The membranes were rinsed 3X (as above) with TBST, incubated with 
streptavidin-alkaline phosphatase and color development steps were followed as described under 
2.3.   
2.9. Electron microscopy 
   Electron microscopy images were made from lysates and CsCl purified lambda display 
preparations by Dr. Hans-W. Ackermann, Department of Medical Biology, Faculty of Medicine, 
Laval University, Quebec, Canada.  
3. Results 
3.1. Demonstration of thermoregulated expression from lambda promoter  
  594 [pD-FLAG] cells are viable at 30
o
C, 37
o
C and 39
o
C but not at 42
o
C (Fig. 4.1a) 
indicating inactivation of heat-labile lambda repressor at 42
o
C which derepresses (induces) 
lambda promoter, leading to cell killing. The same principle was illustrated in another 
experiment. 594 [pD-FLAG] cells were viable when cross streaked on λc172 at 30oC (Fig. 4.1b) 
but became susceptible at 42
o
C (Fig. 4.1c) due to heat inactivation of the repressor which 
otherwise maintained lysogeny and immunity against homologous lambda (λc172) infection. As 
expected, cells were killed by λvir at both temperatures (Fig. 4.1b & 4.1c).    
3.2.   Demonstration of D-CAP and D–FLAG fusion proteins in E. coli cell extracts by WB 
  In order to demonstrate expression of lambda D-fusion proteins in E. coli following 
thermal induction, total protein extracts collected after varying durations at respective 
temperatures were separated and reacted with specific antibodies. The blot reacted with anti-
PCV2 polyclonal from a gnotobiotic pig (Fig. 4.2a) shows bands for D-CAP (24.6 kDa) with 
gradual increase in intensity beginning from the extract corresponding to 20 min through 4 hr of 
incubation at 42
o
C. Similarly, Fig. 4.2B demonstrates bands for D-FLAG (20.7 kDa) with 
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increasing intensity beginning from 20 min to 4 hr incubation at 39
o
C. Neither non-induced nor 
non-transformed cultures yielded bands in these assays. 
3.3. Monitoring bacterial growth and viable phage counts during preparation of lysates of lambda 
displaying D-fusion proteins 
  Bacterial growth and viable phage counts (pfu/ml) were monitored during preparation of 
lysate of lambda displaying D-CAP are presented in Figure 4.3; time points “a” through “g”. 
Actively growing cells containing pD-CAP were infected with λimm434cI at ~0.1 OD575 (point b 
& arrow). Release of progeny viruses was evidenced as early as 1 hr post-infection (point c) 
while bacteria continued to multiply. Cells reached the maximum growth at 2.0 hr post-infection 
(point d) at which point phage titer had also increased by ~1.5 Log10 compared to point c, 
followed by a sharp drop of lysate turbidity within the next 1 hr period (up to point e, 3 hr of 
post-infection) due to cell lysis. This cell lysis was coincided with the burst of progeny viruses, 
as evidenced by the highest phage titer at point e. Lysis of cells progressed slowly for another 2 
hr until it almost plateaued by 5 hr of post-infection (point e through g) during which time phage 
titer also dropped by ~0.5 Log10.    
3.4. Viable (pfu/ml) phage titers in lysates and purified lambda display preparations  
  Phage titers were estimated in three sets of bulk volumes of lambda D-CAP lysates at two 
time points: immediately after preparation, and after 5-12 days (Table 4.1). Titers dropped by a 
factor of 1.5 to 5.8 during this period.  Table 4.2 illustrates titers at each step of lambda display 
preparations. Each lysate had a high initial titer (~10
9
 pfu/ml) which was increased ~2-15 times 
following each PEG pelleting. In this phage concentration process, titers reached a maximum of 
10
11
 to 10
12
 pfu/ml range prior to CsCl gradient centrifugation. Viable phage titers dropped  
dramatically by several Log10  in each of the preparation following CsCl banding.   
3.5. Banding pattern of lysates containing lambda displaying D-CAP expressed in two  
     different expression systems  
  Lysates containing lambda displaying D-CAP were prepared using two expression 
systems i.e., constitutively and by thermal induction. In both occasions, particles were separated 
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in to three bands on the CsCl gradient (Fig. 4.4a & 4.4b, respectively). Bands were labelled as 
top, middle and bottom depending on the location of the tube.  
3.6. Characterization of phage bands of lambda displaying D-fusion proteins  
3.6.1. Banding pattern, densities, viable and total phage titers of lambda displaying D-fusion  
  proteins after first CsCl purification  
  Banding patterns of the three display preparations i.e., D-CAP, D-FLAG and D-GFP, are 
presented in Fig. 4.5. While lambda displaying D-CAP yielded three bands (Fig 4.5a), D-FLAG 
(Fig 4.5b) and D-GFP (Fig 4.5c) were separated into a single band. Visual observation, densities 
and viable phage counts were recorded for phage bands on each of preparation. On D-CAP, the 
top band was faint and contained 6.85 х 105 pfu/ml lambda particles with a density of 1.29 g/cc 
(Fig. 4.5a). The middle band was creamy, wide, loosely arranged, and contained 1.88 х 106 
pfu/ml virus particles with a density of 1.42 g/cc. The bottom band was blue, compact, and 
contained 1.6 х 109 pfu/ml virus particles with a density of 1.5 g/cc. Though viable phage titers 
in these phage bands were significantly lower compared to titers prior to CsCl gradient (Table 
4.2), the number of total phage particles recovered in each band of D-CAP preparation was high 
(top, middle and bottom bands contained 1.7 х 1012, 9.33 х 1012 and 4.4 х 1012 particles per ml, 
respectively) and, therefore, comparable or higher titers were present prior to banding.  
  D-FLAG had a thin blue band containing 6.95 х 103 pfu/ml particles with a density of 
1.53 g/cc (Fig. 4.5b) while D-GFP formed into a creamy and very dense band (Fig. 4.5c) 
containing 3.76 х 109 pfu/ml particles with a density of 1.47 g/cc.  
3.6.2. Demonstration of phage displaying D-CAP by ELISA  
  The ELISA showed higher reactivity throughout a series of middle phage band dilutions 
with anti-PCV2 polyclonal from a gnotobiotic pig compared to corresponding dilutions 
containing equal number of lambda particles from the bottom band of D-CAP or unmodified 
lambda  preparations (Fig. 4.6). This indicates the presence of more D-CAP protein in the middle 
phage band and therefore, it was used as a vaccine candidate to immunize pigs.  
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3.6.3. Demonstration of phage displaying D-CAP by WB 
 The blots reacted with either anti-PCV2 polyclonal from a gnotobiotic pig (Fig. 4.7a) or 
serum from a conventional pig immunized with lambda displaying D-CAP (Fig. 4.7b) revealed 
the D-CAP (arrow) on the lambda display particles (LDP) (lane 3) and the PCV2-Cap (triangle) 
on the PCV2-infected cell lysate (lane 2), respectively. The arrow with double heads on lane 3 of 
Fig. 4.7b showed wild type D in the lambda D-CAP display preparation. There was no 
corresponding D protein band on the unmodified lambda proteins (Fig. 4.7b, lane 4). The blot 
containing proteins from an unmodified lambda preparation reacted with anti-lambda polyclonal 
from a conventional pig (Fig. 4.7c). They include a tail and a head protein (unnamed) of 74 and 
56 kDa respectively, the major head protein E (37 kDa), the major tail protein V (32 kDa) and 
the head protein D (11 kDa).   
  In order to estimate display density of D-CAP in the display vaccine preparation, the 
intensity of D-CAP (arrow) and D-wild type (arrow with double heads) bands on the lambda D-
CAP display preparation (Fig. 4.7b, lane 3) was measured using a commercial software package 
(Northern ECLIPSE, 6.0; Imaging Software, Empix Imaging Inc., Mississauga, Ontario, Canada) 
and revealed D-CAP (61.5%):D-wild type (38.5%). An area on the D-wild type band was first 
demarcated at the same level corresponding D band shown in the Fig 4.7c prior to measure 
intensity of the band.  
3.6.4. Electron microscopy of lambda displaying D-CAP  
  Electron microscopy on both crude lysate (Fig. 4.8a) and CsCl purified lambda 
displaying D-CAP i.e., middle phage band (Fig. 4.8b) illustrates tailless heads compared to intact 
particles in an unmodified lambda lysate (Fig. 4.8c). Arrows and triangles in lambda D-CAP 
preparations (Fig 4.8a, b) indicate heads containing DNA, and proheads i.e., prior to DNA 
encapsidation, respectively. Heads were hexagonal and bigger (~60 nm in diameter) compared to 
round and smaller proheads (~50 nm in diameter). Purified lambda D-CAP preparation (Fig. 
4.8b) shows well separated tailless heads with improved clarity compared to crude lysates (Fig. 
4.8a, c).    
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Fig.4.1 Thermal induction inactivates heat-labile lambda repressor as manifested by cell killing 
  or susceptibility to a homologous lambda infection: (a) lysogen used to transform  
 plasmids coding for D-FLAG were killed at 42
o
C, (b) immune to homologous lambda 
 infection (λc172) at 30oC but (c) become susceptible for the infection at 42oC. Arrows 
 indicate direction of cross streaking. 
a 
λ vir  λ c172
  
λ vir  λ c172
  
b c  
 
30oC 42oC 
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Fig. 4.2 Western blots demonstrating expression of D-CAP and D-FLAG in E. coli 
transformed with respective plasmids by thermal induction for varying periods of 
incubation: (a) D-CAP at 42
o
C and (b) D-FLAG 39
oC. “No induction” corresponds to 
extracts from cells containing the plasmid but not thermally induced. “No plasmids” 
indicate that the cells were not transformed with plasmids but were thermally induced. 
Other lanes are labelled by duration of incubation. 
 
 
 
 
 
 
 
 
 
 
a 
b 
No Induction         20 min 1 hr        3 hr        4 hr No plasmid
  
D-CAP 
D-FLAG 
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Fig. 4.3 Growth curve of E. coli transformed with pD-CAP during the preparation of 
lysate containing lambda displayed D-CAP at 39
o
C.  Growth medium was 
inoculated with E. coli at point a. Optical densities (OD575) and viable phage titers 
(pfu/ml) were measured from point a through g. Time of phage infection (arrow) 
and titers thereafter are indicated along with the corresponding stage of 
incubation. 
 
Time (hr) of incubation 
Lambda infection 
Bacterial inoculation 
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Fig. 4.4 The banding pattern of lambda displayed D-CAP in CsCl gradients produced 
using two expression systems: (a) λimm434cI infection in E. coli lacking thermo 
regulatory promoter activity transformed with pD-CAP (D-CAP expressed 
constitutively)  (b) λimm434cI infection in E. coli containing thermo regulatory 
promoter transformed with pD-CAP (D-CAP expressed by thermal induction). 
Phage bands were identified by their location in the tube. The top white layer was 
protein excluded from the gradient. 
 
 
Top band 
Middle band 
Bottom band 
Protein layer 
a b 
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Fig. 4.5 The banding pattern of lambda displaying (a) D-CAP (b) D-FLAG and (c) D-GFP in 
CsCl gradients produced by lambda infection in thermally induced E. coli containing 
respective plasmids at 39
o
C. The densities of each band are indicated by arrows.  
 
 
 
 
 
 
 
a b c 
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Fig. 4.6 ELISA measuring phage displayed D-CAP fusion protein using anti-PCV2 
polyclonal antiserum from a gnotobiotic pig. Serial dilutions of middle (   ) and 
bottom bands (■) of lambda D-CAP preparation along with unmodified lambda 
(▲) contain equivalent number of phage particles. The number of phage particles 
coated in undiluted preparation was 3×10
10 
per well. 
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Fig. 4.7 Western blots demonstrating lambda displayed D-CAP and other major lambda proteins: 
(a) blot reacted with anti-PCV2 polyclonal antiserum from a gnotobiotic pig, (b) anti-D-
CAP polyclonal antiserum from a conventional pig and (c) anti-lambda polyclonal 
antiserum from a conventional pig. Lanes; 1) Protein mass marker, 2) partially purified 
PCV2 antigen from PK15 infected cells, 3) LDP-D-CAP from heat-disrupted phage 
particles, and 4) similarly disrupted unmodified phage particles. Arrow, triangle and 
arrow with double heads indicates D-CAP, PCV2-Cap (positive control) and lambda D 
proteins respectively. Major lambda protein bands are identified on the blot c. 
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Fig. 4.8 Electron microscopy graphs showing lambda displaying D-CAP: (a) crude lysate and (b) 
twice CsCl purified middle band of lambda D-CAP preparation demonstrating tailless 
heads in comparison to (c) intact particles in an unmodified lambda lysate. Arrows and 
triangles indicate hexagonal relatively bigger heads and rounded smaller proheads, 
respectively. Magnification ×148,500. 
b 
c 
a 
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Table 4.1 
Monitoring of phage titers (pfu/ml) in lysates of lambda displayed D-CAP stored at 4
o
C. 
Lysate ID  Original titer on the  Subsequent          Time gap (day)  
& volume  day of preparation  titration    between titrations 
Batch A (1L)  9.6 х 108   6.0 х 108   12  
Batch B (2L)  4.6 х 109   2.6 х 109   7   
Batch C (4L)  2.6 х 109   4.5 х 108   5  
  
 
 
 
Table 4.2 
Titers (pfu/ml) of phage displaying fusion proteins after each step of the preparation.  
Phage display   Lysate Post 1
st
 PEG  Post 2
nd
 PEG  Post 1
st
 CsCl  Post 2
nd
 CsCl 
preparation   Pelleting  Pelleting  purification purification 
D-CAP 9.54 х 109 2.8 х 1011 5.52 х 1012  a1.88 х 106 a3.75 х 105  
D-FLAG 6.75 х 109 1.95 х 1011 1.8 х 1012  6.95 х 103 bN  
D-GFP  5.00 х 109  7.2 х 1010 9 х 1011  3.76 х 109 bN  
Unmodified 8.62 х 109 2.97 х 1010 2.91 х 1011  1.4 х 109 bN              
a
 Middle phage band  
b 
Not titrated 
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4. Discussion 
 This study was undertaken to investigate the feasibility of producing a lambda 
display preparation using a safe method with, an intention of application in biological systems. 
We chose to express display peptides through plasmids, rather than cloning extraneous genes 
into lambda that could propagate in the event of escaping into the environment. In our method, 
particles displaying respective fusion peptides were produced only when the lysogen containing 
the plasmid was infected with a specific lambda phage at a desired temperature. Further, 
expression of proteins through a plasmid does not necessitate each copy of lambda D protein to 
be fused with the display peptide, rather it yields mosaic phage particles bearing both wild type 
D and those fused with display peptides, causing less impact on morphogenesis and integrity of 
the particle [189, 278]. In our expression system, D-fusion proteins were transcribed from the 
plasmid. Whereas, wild type D protein was supplied via the expression of an infecting wild type 
lambda genome.  
The nucleotide sequences for D-fusion peptides were codon optimized for E. coli 
avoiding restriction enzyme sites, sequenced, synthetically made and included in a set of 
commercial plasmids containing antibiotic resistant cassettes and additional cloning sites. Fusion 
peptide sequences were codon optimized to ensure their synthesis in E. coli and to minimize the 
possibility of digestion by host enzymes [278, 282]. The display proteins (D-CAP, D-FLAG and 
D-GFP) were fused to the C-terminal of lambda D protein by a five-amino acid flexible linker 
that may allow fusion peptide to position outward and make them readily available for intended 
function. A similar study has used a linker with alternating proline and threonine repeats 
allowing independent folding of both D and the D-fusion proteins [233]. C-terminal of lambda D 
is preferred for fusing peptides because of higher display density compared to N-terminal fusions 
[238].  
 Our initial experiments confirmed thermal induction of lambda promoter. This system 
has the ability to control expression of fusion peptides and, thereby, avoiding spontaneous build 
up of potential toxic peptides in E. coli prior to thermal induction [188]. Heat inducible lambda 
functions i.e., cell killing and protein synthesis, are associated with inactivation of a heat-labile 
repressor protein, a product of lambda c1gene [279]. This protein is also responsible for 
maintaining the prophage (lysogeny) and, therefore, its inactivation may switch the lysogenic 
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state into the lytic pathway and produce progeny viruses. However, there are certain lambda 
mutants which do not produce progeny viruses although they were thermally induced for protein 
synthesis. Therefore, cell killing is suggested to be mediated by an enzyme [279]. Thermal 
inductions were attempted between 38-43
o
C and non-lysogen or lysogen containing wild-type 
lambda do not die at these temperatures [279]. As long as prophage is maintained by this heat-
labile repressor at 30
o
C, it does not allow the bacterium (lysogen) to be reinfected with 
homologous lambda, i.e., λc172 (immunity), but it become susceptible at 42oC with the 
inactivation of the repressor. The immunity is lambda type specific and, therefore, other lambda 
types i.e., λvir can infect the lysogen harbouring λc1 prophage either at 30oC or 42oC [279, 283].  
We demonstrated expression of D-CAP and D-FLAG by WB and confirmed thermal 
induction of these proteins in E. coli. Expression of both of these display peptides was evident by 
specific bands of predicted molecular weight (24.6 and 20.7 kDa for D-CAP and D-FLAG, 
respectively) and duration of incubation dependent increase in the band size. Importantly, both 
the non-induced and the non-transformed cell extracts were negative for the presence of fusion 
polypeptides. We chose FLAG as a fusion protein because its expression was successfully 
demonstrated in E. coli as a tag protein [281]. Expression of D-CAP was attempted with the 
intention of displaying it fused to lambda head D protein for use as a vaccine candidate for 
porcine Circovirus 2 (PCV2). To achieve this goal, we prepared bulk volumes of lysates of 
lambda displaying these fusion peptides. The production procedure was standardized and 
demonstrated a characteristic bacterial growth curve during the process. Complete cell lysis was 
observed ~5 h post-infection at 39
o
C with a burst of phage release as indicated by a sharp 
increase in viable titers (pfu/ml). A decline in titer on further incubation was likely be due to 
attachment of lambda particles to E. coli cell debris. Therefore, lysates were immediately 
clarified from cell debris and particles were subsequently concentrated by double PEG pelleting 
and purified by CsCl density gradient ultracentrifugation [191, 278, 284].  
We were successful in obtaining phage bands in every lambda display preparation 
although the banding patterns were different among them. Isolated bands had a minimum viable 
titer of ~7 х 103 pfu/ml (D-FLAG band) and total phage titer as high as ~1 х 1013 (middle band 
of D-CAP preparation).  In contrast, lysates of lambda display preparation that supposedly 
contained particles bearing only the D-fusion peptides without wild type D did not yield any 
95 
 
bands because of  incomplete phage morphogenesis, indicating the significance of leaving a 
certain number of wild type D on the phage particle [278]. In order to characterize the D-CAP 
bands, the two major bands i.e., middle and bottom, along with an unmodified lambda 
preparation were reacted with anti-PCV2 polyclonal antiserum from a gnotobiotic pig in an 
ELISA. Higher reactivity in the middle phage band is likely due to its higher proportion of 
particles displaying D-CAP fusion proteins compared to the bottom band that contained few or 
no particles displaying D-CAP. This could result in a higher protein:DNA ratio per particle in the 
middle band and, therefore, lighter (banded higher in the tube) than the bottom band with a 
density comparable to regular lambda (1.5 g/cc) [285]. Accordingly, the top band though very 
faint, may have had the highest D-CAP content. The minute quantity of this band recovered was 
not adequate to test this possibility. Electron microscopy provided crucial evidence for further 
explanation of the lambda D-CAP banding pattern. Crude lysate of this preparation contained 
mostly tailless heads and few intact particles, while the CsCl purified middle band contained 
only the tailless heads. Most heads in the middle band were either empty or only partially filled 
with DNA compared to unmodified lambda preparation that contained intact particles with 
electron dense heads, i.e., heads full with DNA. These EM data on lambda D-CAP preparation 
provided vital evidence of both the influence of lambda heads displaying D-CAP on their 
assembly with tails, and the banding pattern of this display preparation. D-CAP fused empty or 
partially full heads were likely higher in protein:DNA ratio per particle and, therefore, banded at 
relatively higher position (lower density) compared to intact and/or less D-CAP rich particles in 
the bottom phage band. This possibility of relatively denser intact particles separated into the 
bottom band was evident by its three Log10 higher viable phage titer compared to that of the 
middle band. We analysed only the CsCl purified middle band of D-CAP preparation partly 
because of its higher reactivity with anti-PCV2 antibodies and therefore, our interest in its use as 
a vaccine candidate. Further, there were technical difficulties with handling phage preparations 
in CsCl for EM analysis. We attempted EM on crude lysates of other display preparations but 
were unable to demonstrate any phage particles. It is also important to indicate that we observed 
the same banding pattern of lambda D-CAP preparation consistently over two batches. The first 
batch was prepared using cells devoid of heat-labile repressor (constitutive expression) and the 
other was prepared using cells with heat-labile repressor (thermally induced expression). 
Therefore, separation into three bands seemed characteristic of the lambda D-CAP preparation. 
96 
 
On further  investigation of the functional significance of lambda displaying fusion peptides, one 
of our display preparations i.e., middle band of D-CAP which showed higher reactivity with anti-
PCV2 antibodies was used in an immunization trial in pigs [277]. The pigs developed PCV2 
specific humoral and cell-mediated immunity indicating functional integrity of the lambda 
displaying D-CAP. There are several similar vaccine candidates that have been developed 
though using other bacteriophage display systems [228-231].  
We confirmed that our vaccine candidate contained lambda displaying D-CAP by WB 
using anti-PCV2 polyclonal antiserum from a gnotobiotic pig. A single band of D-CAP (24.6 
kDa, calculated) was observed on the vaccine particles (purified middle band of D-CAP 
preparation), without staining any other lambda bands with this sera, indicated the specificity of 
the reaction. A similar blot reacted with sera after immunization revealed the D-CAP band along 
with major head protein E and wild type D on the same preparation confirming particles carried 
both wild type and D-fusion peptides.  Interestingly, sera collected after immunization did react 
with all but D protein on the unmodified lambda phage preparation, suggesting a possibility of 
masking wild type D by D-CAP in the vaccine preparation and, therefore, not induced anti-D 
antibodies.  In order to confirm this possibility, we compared regular/unmodified lambda 
proteins stained with anti-lambda polyclonal raised in a conventional pig. This experiment 
demonstrated bands corresponding to all lambda major proteins including D (11 kDa) providing 
further evidence to our explanation. Display density of D-CAP in our vaccine preparation was 
reasonably high (61.5%) and comparable with similar studies [238, 278]. Density of display 
peptides depends on their size, i.e., the smaller the size of the peptides the higher the display 
density [189, 286]. Electron microscopy on lambda D-CAP preparation revealed only tailless 
particles. This EM evidence and positive identification by anti-PCV2 polyclonal from a 
gnotobiotic pig confirm the band on the vaccine preparation to be D-CAP although it migrated to 
a position that corresponds to regular lambda V protein. On the other hand, sera from a pig 
vaccinated with CsCl purified lambda display particles showed anti-V reactivity. Taking all these 
experimental evidences into consideration, it is likely that some tail protein could also be fused 
with lambda heads displaying D-CAP. 
 Electron microscopy graphs demonstrating tailless heads in the lambda D-CAP 
preparation suggested of interference on lambda head assembly with their tails, most likely due 
97 
 
to alteration of head architecture by display peptides. Comparing EM analysis on crude lysate 
and purified middle band of this preparation revealed the former contained heads relatively full 
of DNA compared to the latter obtained by double CsCl centrifugation. This observation raises a 
possibility of unstable or leaky lambda heads due to their fusion with display peptides and 
therefore lost DNA during ultracentrifugation. We have observed loss of viable titers in the 
lysates of display preparations, and most dramatically after CsCl gradient centrifugation, 
providing further evidence to support this possibility. Intact lambda particles were reported to 
maintain titers much longer period (~30 years) [287] suggesting instability of particles displaying 
peptides, leading to loss of their infectivity. Among the three display preparation, the most 
dramatic loss of titer was observed in lambda D-FLAG preparation after the first CsCl gradient 
centrifugation.  
 In summary, we have attempted displaying three types of display peptides fused to 
lambda head D protein using a safer expression system to be applied on biological systems. We 
have shown display of D-CAP and the functional significance of this peptide as a vaccine 
candidate. We are not certain why other display preparations did not demonstrate particles by 
EM.  
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GENERAL CONCLUSIONS 
1. Piglet vaccination may be negatively affected by passively acquired maternal PCV2 
antibodies as suggested by my studies as well as other reports. I investigated if the 
parenteral administration of a prototype, adjuvanted, PCV2 vaccine to piglets at an early 
age could override passive immunity, and could induce acquired immunity in young 
piglets. My results were not conclusive. They suggested that further investigations were 
required that involved varying vaccine antigen doses in combination with different 
adjuvants to piglets with defined concentrations of maternally-derived PCV2 antibodies.  
2. Preexisting anti-lambda antibodies in pigs could interfere with immune induction by a 
lambda phage display PCV2 vaccine candidate. Sera from 55 farm pigs were tested for 
anti-lambda antibodies by ELISA in comparison to known negative and positive sera. 
The pigs contained very low (or no) anti-lambda antibodies. This suggested that a lambda 
phage vaccine can be administered into pigs without the risk of suppressing the target 
vaccine antigen specific immune response.  
3. We chose to induce lambda D-fusion peptides from plasmids within transformed E. coli 
cells. Protein extracts of the thermally induced cells were tested for expression of D-
fusion peptides by Western blots. These experiments demonstrated the expression of D-
CAP and D-FLAG fusion proteins from a thermally inducible protein expression system 
in E. coli.     
4. Lambda particles displaying D-fusion peptides, D-CAP, D-FLAG and D-GFP, were 
produced by infecting thermally induced E. coli expressing respective D-fusion peptides 
with lambda and purifying the display particles by double CsCl gradient centrifugation. 
The phage bands were characterized based on their densities, viable titers, electron 
microscopy and immunological assays (ELISA and Western blots).  
5. Conventional pigs were immunized with lambda particles displaying D-CAP without an 
adjuvant, in two separate vaccination trials. These experiments showed induction of anti-
PCV2 humoral and cell-mediated immunity, and the presence of virus neutralizing 
antibodies. This preparation served as the first display vaccine candidate produced using 
phage lambda. 
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